Relevant data are available on figshare.com: (<http://dx.doi.org/10.6084/m9.figshare.1431538>).

Introduction {#sec007}
============

Migraine headaches are common, with a worldwide prevalence ranging between 8 and 18% \[[@pone.0130733.ref001]--[@pone.0130733.ref007]\]. Migraines cause significant disability \[[@pone.0130733.ref008]--[@pone.0130733.ref011]\], even during periods between attacks \[[@pone.0130733.ref012]\], and are responsible for \$1 billion in medical costs and \$16 billion in lost productivity per year \[[@pone.0130733.ref013],[@pone.0130733.ref014]\] in the US alone. The diagnostic criteria for migraine headaches have evolved over time. Currently, the International Headache Society (IHS) diagnostic criteria for migraine includes having at least 5 attacks that last 4--72 hours, that are unilateral, pulsating, moderate or severe in intensity and aggravated by or cause avoidance of routine physical activity and are also accompanied by nausea and/or vomiting, photophobia or phonophobia \[[@pone.0130733.ref015]\]. IHS further classifies migraine as with or without an aura and as episodic or chronic. Chronic migraine is defined as more than 15 migraine headaches per month for more than 3 months. Chronic migraines result in significantly greater disability than episodic migraines\[[@pone.0130733.ref016]\].

Treatment of headaches can be either abortive or prophylactic. Abortive treatment provides symptom relief for the acute headache \[[@pone.0130733.ref017],[@pone.0130733.ref018]\], while prophylactic treatment aims to reduce the frequency or severity of headaches over time. We focus on prophylactic migraine headache treatment in this manuscript. There are a large number of prophylactic treatment options available; common ones include alpha antagonists, anti-convulsants \[[@pone.0130733.ref019]\], beta-blockers \[[@pone.0130733.ref020]\], botulinum-A \[[@pone.0130733.ref021]\], calcium channel blockers \[[@pone.0130733.ref022]\], serotonin agonists\[[@pone.0130733.ref023]\], serotonin reuptake inhibitors (SSRIs) \[[@pone.0130733.ref024]\] and tricyclic antidepressants (TCAs) \[[@pone.0130733.ref025]\]. Two emerging prophylactic candidates are angiotensin converting enzymes (ACE) and angiotensin receptor antagonists (ARB). Unfortunately nearly half of males and a third of females who are candidates for prophylactic therapy do not receive it \[[@pone.0130733.ref026]\]. Selection of prophylactic treatment is tailored on individual patient characteristics, costs and side effects of the available options. However, for patients and their providers, the decision about which prophylactic regimen to use is hampered by the lack of head to head trials comparing the different classes of medications. In addition, previous systematic reviews have focused on single classes of drugs. Two recent systematic reviews that looked more broadly at different drug options have been published. One only included studies since 1999 and did not pool any results, providing qualitative statements about relative treatment effectiveness \[[@pone.0130733.ref027]\]. Another review analyzed focused only on dichotomous outcomes among patients with episodic migraines and found no difference in likelihood of experiencing at least 50% improvement in headaches between different classes of oral medications \[[@pone.0130733.ref028]\]. Previous systematic reviews have also had methodological problems. Some combine outcomes from the end of the study, regardless of study duration. This inappropriately combines study results at markedly different time points. This also tends to overstate the strength of the evidence by making it appear that there are more studies contributing data to the results and produces inappropriately narrow confidence intervals. We conducted a meta-analysis asking what is the comparative effectiveness and side effects of the prophylactic treatment of migraine headaches in adults using oral pharmacological medications.

Materials and Methods {#sec008}
=====================

This report closely adheres to the PRISMA guidelines for conducting a systematic review \[[@pone.0130733.ref029]\]. We searched MEDLINE, EMBASE, the bibliographies of all retrieved articles, published systematic reviews and the Cochrane Database of Clinical Trials for each of the classes of medications ([Table 1](#pone.0130733.t001){ref-type="table"}) through 7 November 2014. The search was conducted independently in duplicate. We included published, randomized clinical trials that evaluated efficacy in reducing the frequency or severity of migraine headaches that were at least 4 weeks in duration among adults. These comparisons could be between active treatment with placebo controls or comparative trials comparing two or more active treatments. We did not include unpublished data as there is no systematic means of searching for it. Because the classification of headache has changed over time \[[@pone.0130733.ref030],[@pone.0130733.ref031]\], two authors independently reviewed each included article\'s headache definition and, where possible, classified it according to the 3rd edition of the International Headache Society (IHS) criteria (ICDH-III) and included only those that could reasonably be defined based on these diagnostic criteria \[[@pone.0130733.ref015]\]. For headache trials before 2004, we classified trials as focusing on episodic or chronic migraine based on the number of headaches experienced by participants at baseline.

10.1371/journal.pone.0130733.t001

###### Search Strategies.

![](pone.0130733.t001){#pone.0130733.t001g}

  Search Purpose                             Search Strategy
  ------------------------------------------ ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Headaches                                  (headache OR headache disorders OR migrain[\*](#t001fn001){ref-type="table-fn"} OR headache[\*](#t001fn001){ref-type="table-fn"} OR cephalgi[\*](#t001fn001){ref-type="table-fn"} OR cephalalgi[\*](#t001fn001){ref-type="table-fn"} OR tension[\*](#t001fn001){ref-type="table-fn"})
  Randomized controlled trials               (randomized controlled trial \[pt\] OR controlled clinical trial \[pt\] OR randomized controlled trials \[mh\] OR random allocation \[mh\] OR double-blind method \[mh\] OR single-blind method \[mh\] OR clinical trial \[pt\] OR clinical trials \[mh\] OR (\"clinical trial\" \[tw\]) OR ((singl[\*](#t001fn001){ref-type="table-fn"} \[tw\] OR doubl[\*](#t001fn001){ref-type="table-fn"} \[tw\] OR trebl[\*](#t001fn001){ref-type="table-fn"} \[tw\] OR tripl[\*](#t001fn001){ref-type="table-fn"} \[tw\]) AND (mask[\*](#t001fn001){ref-type="table-fn"} \[tw\] OR blind[\*](#t001fn001){ref-type="table-fn"} \[tw\])) OR (placebos \[mh\] OR placebo[\*](#t001fn001){ref-type="table-fn"} \[tw\] OR random[\*](#t001fn001){ref-type="table-fn"} \[tw\] OR research design \[mh:noexp\] OR comparative study \[mh\] OR evaluation studies \[mh\] OR follow-up studies \[mh\] OR prospective studies \[mh\] OR control[\*](#t001fn001){ref-type="table-fn"} \[tw\] OR prospectiv[\*](#t001fn001){ref-type="table-fn"} \[tw\] OR volunteer[\*](#t001fn001){ref-type="table-fn"} \[tw\]) NOT (animals \[mh\] NOT humans \[mh\])
  Alpha blockers                             ("Adrenergic alpha-Antagonists"\[MeSH Terms\]or clonidine OR tizanidine)
  Angiotension converting enzyme inhibitor   "Angiotenin-Converting Enzyme Inhibitors" \[mh\] OR benzapril OR captopril OR enalapril OR lisinopril OR moexipril OR perindopril OR quinapril OR ramipril OR trandolapril
  Angiotension receptor blockers             "Angiotensin Receptor Antagonists" \[mh\] OR losartan OR irbesartan OR olmesartan OR candesartan OR valsartan OR telmisartan
  Anticonvulsants                            ((anticonvulsants \[mh\] OR (anticonvulsant[\*](#t001fn001){ref-type="table-fn"} OR antiepileptic[\*](#t001fn001){ref-type="table-fn"} OR acetazolamide OR carbamazepine OR chlormethiazole OR clobazam OR clorazepate OR divalproex OR ethosuximide OR felbamate OR fosphenytoin OR gabapentin OR lamotrigine OR levetiracetam OR mephobarbital OR methsuximide OR midazolam OR oxcarbazepine OR paraldehyde OR pentobarbital OR phenobarbital OR phenytoin OR primidone OR valproate OR tiagabine OR topiramate OR valproic[\*](#t001fn001){ref-type="table-fn"} OR vigabatrin OR zonisamide)
  Beta-blocker                               adrenergic beta receptor blockaders \[mh\] OR (alprenolol OR bucindolol OR carteolol OR carvedilol OR labetalol OR nadolol OR penbutolol OR pindolol OR propranolol OR Sotalol OR timolol OR acebutolol OR atenolol OR betaxolol OR bisoprolol OR celiprolol OR esmolol OR metoprolol OR nebivolol)
  Calcium channel blocker                    (calcium channel blockers/therapeutic use\"\[mh\] OR (amlodipine OR aranidipine OR azelnidipine OR barnidipine OR benidipine OR bepridil OR cilnidipine OR clevidipine OR diltiazem OR efonidipine OR felodipine OR fendiline OR flunarizine OR fluspirilene OR gallopamil OR isradipine OR lacidipine OR lercanidipine OR manidipine OR mibefradil OR nicardipine OR nifedipine OR nilvadipine OR nimodipine OR nisoldipine OR nitrendipine OR pranidipine OR verapamil))
  Selective serotonin reuptake inhibitor     serotonin Uptake Inhibitors/therapeutic use \[MH\] OR (citalopram OR dapoxetine OR escitalopram OR fluoxetine OR fluvoxamine OR indalpine OR paroxetine OR sertraline OR vilazodone OR zimelidine OR venlafaxine OR desvenlafaxine OR duloxetine OR milnacipran OR levomilnacipran OR sibutramine OR bicifadine)
  Serotonin agonist (Pizotifen)              Pizotyline \[mh\] OR pizotifen OR sandomigran
  Tricyclic antidepressant                   antidepressive agents, tricyclic OR antidepressive\$ OR tricyclic\$ OR amitriptyline OR amoxapine OR clomipramine OR desipramine OR dibenzepin OR dothiepin OR doxepin OR imipramine OR lofepramine OR nortriptyline OR opipramol OR protriptyline OR trimipramine

\* (is the symbol for wild-card in MEDLINE)

Two authors independently abstracted data. Because measures of headache outcomes varied, a priori we followed International Headache Society outcome recommendations by prioritizing abstraction and analysis in this order: 1) headache frequency, 2) a headache index that included frequency, 3) severity or 4) duration \[[@pone.0130733.ref032]\]. Headache frequency was standardized to number of headaches per month. Whenever possible, we pooled frequency as the number of headaches/month. When not possible, we pooled standardized mean differences between studies, a measure also known as an effect size. By convention, effect sizes greater than 0.8 are considered to be large effect sizes, 0.5--0.8 moderate and 0.2--0.5 small \[[@pone.0130733.ref033]\]. When missing, variances were calculated from reported mean, sample size and p values \[[@pone.0130733.ref034]\]; for one non-placebo comparison trial \[[@pone.0130733.ref035]\] variance was imputed based on sample size and the reported effect size (r^2^ = 0.76) When not explicitly reported, to verify we were using the proper variance, we tested the abstracted data for each article to ensure that the p value reported in the article matched our analysis. This helped insure that standard errors weren't abstracted as standard deviations, a common error in systematic reviews \[[@pone.0130733.ref036]\]. In addition, because of reports on the potential for misleading data \[[@pone.0130733.ref037],[@pone.0130733.ref038]\], we only accepted data that was unadjusted and that was either based on a true intention to treat analysis or based on the subjects remaining in the trial. We rejected any "modified intention to treat" analyses or analyses subject to other adjustments. We assessed article quality independently and in duplicate, using both component and scales approaches using the Cochrane Risk of Bias Tool \[[@pone.0130733.ref039]\] and the Jadad scale \[[@pone.0130733.ref040]\] with good inter-rater agreement (Cochrane ICC: 0.83; Jadad kappa: 0.85). Disagreements were resolved by consensus.

For studies with more than one arm or using a cross-over design, we followed the recommendations of the Cochrane collaboration by pooling the arms into a single arm (if the study reported no differences between arms) or by reducing the sample sizes for cross-over trials by 50% \[[@pone.0130733.ref041]\]. We abstracted data from each trial at the following time points: baseline, 4, 8, 12, 24, 30 and 36 weeks using the DerSimonian and Laird random effects model \[[@pone.0130733.ref042]\]. Because of controversy about the accuracy of reporting of off-label use of one of gabapentin \[[@pone.0130733.ref037],[@pone.0130733.ref038]\], we relied on data in McCrory's reanalysis of misleading data presented in one of the studies \[[@pone.0130733.ref043]\] based on drug company trial data.

The main focus of our analysis is between active treatment and placebo controls. We also included data from comparative effectiveness trials. In addition to direct comparisons between drugs, we also conducted a network meta-analysis \[[@pone.0130733.ref044]--[@pone.0130733.ref047]\]. In brief, network meta-analysis asks if one drug has a pooled efficacy compared to placebo of X and another drug has a pooled efficacy compared to placebo of Y, are X and Y statistically different? We only included drugs with at least 2 clinical trials and at least 8 weeks in duration, adjusting for duration and for correlation between outcomes reported from the same trial. Because these studies did not always report their outcomes in frequency of headaches, the network meta-analysis was done using standardized mean differences (SMD) rather than weighted mean differences.

Heterogeneity was assessed visually using Galbraith plots \[[@pone.0130733.ref048]\], and I-square \[[@pone.0130733.ref049]\].We assessed for small study effects (publication bias) using the methods of Peters \[[@pone.0130733.ref050]\] for dichotomous outcomes and Eggers \[[@pone.0130733.ref051]\] for continuous ones. We explored the potential source of heterogeneity using stratified analysis and random-effects meta-regression \[[@pone.0130733.ref052]\]. These analyses included assessment of the impact of quality, study duration, percentage women, losses to follow-up, and drug dose. All analyses were done using STATA (v 13.1, College Station TX). There was no external funding for this study.

Results {#sec009}
=======

Individual searches yielded 4789 unique articles: 138 ACE, 195 alpha blockers, 109 ARB, 1391 anticonvulsants, 654 beta blockers, 711 calcium channel blockers, 279 serotonin agonists, 363 SSRI and 876 TCA publications. Application of inclusion criteria ([Fig 1](#pone.0130733.g001){ref-type="fig"}) resulted in selecting 179 randomized clinical trials. These included the following placebo controlled trials: 9 alpha blockers \[[@pone.0130733.ref053]--[@pone.0130733.ref061]\], 3 ACE trials \[[@pone.0130733.ref062]--[@pone.0130733.ref064]\] 3 ARB \[[@pone.0130733.ref065]--[@pone.0130733.ref067]\], 33 anticonvulsants \[[@pone.0130733.ref043],[@pone.0130733.ref068]--[@pone.0130733.ref099]\], 39 beta-blockers \[[@pone.0130733.ref066],[@pone.0130733.ref073],[@pone.0130733.ref100]--[@pone.0130733.ref136]\], 12 calcium channel blocker \[[@pone.0130733.ref106],[@pone.0130733.ref137]--[@pone.0130733.ref147]\], 7 flunarizine \[[@pone.0130733.ref148]--[@pone.0130733.ref154]\], 6 SSRI \[[@pone.0130733.ref155]--[@pone.0130733.ref160]\], 1 SNRI \[[@pone.0130733.ref161]\], 9 serotonin agonists \[[@pone.0130733.ref162]--[@pone.0130733.ref170]\] and 9 TCA \[[@pone.0130733.ref118],[@pone.0130733.ref136],[@pone.0130733.ref171]--[@pone.0130733.ref177]\] trials. Fifteen of these placebo-controlled trials included more than one active treatment \[[@pone.0130733.ref066],[@pone.0130733.ref074],[@pone.0130733.ref106],[@pone.0130733.ref116],[@pone.0130733.ref118],[@pone.0130733.ref131],[@pone.0130733.ref136],[@pone.0130733.ref141],[@pone.0130733.ref163],[@pone.0130733.ref167],[@pone.0130733.ref169],[@pone.0130733.ref170],[@pone.0130733.ref175],[@pone.0130733.ref178],[@pone.0130733.ref179]\]. In addition, we also include 53 non-placebo controlled comparative effectiveness trials \[[@pone.0130733.ref178]--[@pone.0130733.ref230]\].

![PRISMA Flowchart of study selection.](pone.0130733.g001){#pone.0130733.g001}

Placebo Comparisons {#sec010}
-------------------

[Table 2](#pone.0130733.t002){ref-type="table"} provides study characteristics of trials investigating prophylactic treatment of episodic migraines (\< 15 headaches/month), [Table 3](#pone.0130733.t003){ref-type="table"} provides details about studies of chronic migraine (\>15 headaches/month) and chronic daily headache. There were a total of 15,493 participants in the placebo controlled trials. Studies averaged 112 participants, ranging from 9 to 783. The average patient was 39.2 years old and 78% of subjects were women. Included studies averaged 12 weeks in duration (range 4--82) and had a mean dropout rate of 24%. Thirty nine trials used the 1962 Ad Hoc Committee criteria, seven used the 1969 World Federation of Neurology criteria, forty seven studies used the 1988 International Headache Society criteria, and sixteen the 2004 IHS criteria. Among included trials, most (n = 120) studied episodic migraine headaches with subjects averaging 5.6 headaches per month (range 1.2--11.7). Ten studies focused on subjects with chronic migraine with an average of 18.6 (range 12--24) headaches a month. Six studied chronic daily headaches; the majority of participants (73%) had chronic migraine. Ninety trials (57%) used a parallel-group design, while sixty-six used a crossover design. There were 23 countries contributing studies. Fifty-one trials (46%) were sponsored by industry. Most studies (82%) used frequency as their outcome measure, nineteen (13.7%) used a headache index, two used headache duration and three headache intensity.

10.1371/journal.pone.0130733.t002

###### Study characteristics of included randomized trials of treatment of episodic (\<15 headaches/month) migraine headaches.

![](pone.0130733.t002){#pone.0130733.t002g}

  Author, year, Country                                                                     Migraine Type                  Baseline Headache Frequency   Drugs (mg)                                Headache Measure   Study design (washout)   Duration, weeks   Sample size   Dropouts   Age          Female
  ----------------------------------------------------------------------------------------- ------------------------------ ----------------------------- ----------------------------------------- ------------------ ------------------------ ----------------- ------------- ---------- ------------ --------
  **ALPHA BLOCKER**                                                                                                                                                                                                                                                                                    
  Adam \[[@pone.0130733.ref053]\], 1978, UK                                                 Episodic                       ns                            Clonidine (0.15)                          Frequency          Crossover (0)            24                96            27%        37.5         84%
  Boison \[[@pone.0130733.ref054]\], 1978, Denmark                                          Episodic                       ns                            Clonidine (0.1)                           Frequency          Crossover (0)            8                 71            31%        ns           ns
  Bredfeldt\[[@pone.0130733.ref055]\], 1989, USA                                            Episodic                       ns                            Clonidine (0.2)                           Frequency          Crossover                6                 43            30%        ns           80%
  Lynggaard \[[@pone.0130733.ref056]\], 1975, Denmark                                       Episodic                       ns                            Clonidine (0.1)                           Frequency          Crossover (1)            12                37            26%        34.1         95%
  Mondrup\[[@pone.0130733.ref057]\], 1977, Denmark                                          Episodic                       ns                            Clonidine (0.1)                           Frequency          Crossover (4)            12                32            34%        35           76%
  Ryan \[[@pone.0130733.ref058]\], 1975, USA                                                Episodic                       ns                            Clonidine (0.15)                          Frequency          Crossover (2 days)       8                 133           ns         41           78%
  Shafar \[[@pone.0130733.ref060]\], 1972, UK                                               Episodic                       8.4                           Clonidine (0.1)                           Frequency          Crossover                8                 65            23%        47.4         84%
  Stensrud, 1976, Norway                                                                    Episodic                       5.8                           Clonidine (0.15)                          Frequency          Crossover (0)            7                 29            7%         43.3         83%
  **ANGIOTENSIN ENZYME CONVERTING INHIBITORS**                                                                                                                                                                                                                                                         
  Paterna \[[@pone.0130733.ref062]\] 1992, Italy                                            Episodic                                                     Captopril (75)                            Headache Index     Crossover                16                20            23%        37           81%
  Schrader \[[@pone.0130733.ref063]\] 2001,Norway                                           Episodic                       2.3                           Lisinopril (20)                           Frequency          Parallel                 12                30            5%         41           81%
  Sonbolestan \[[@pone.0130733.ref064]\], 2013, Iran                                        Episodic                       11.3                          Enalapril (10)                            Frequency          Parallel                 8                 34            0%         34.4         825
  **ANGIOTENSIN RECEPTOR BLOCKER**                                                                                                                                                                                                                                                                     
  Diener\[[@pone.0130733.ref065]\] 2009, Germany                                            Episodic                       6.9                           Telmisartan (80)                          Frequency          Parallel                 12                95            5%         47           85%
  Stovner\[[@pone.0130733.ref066]\], 2013, Norway                                           Episodic                       4.8                           Candesartan (16), Propranolol (160)       Frequency          Crossover                12                61            15%        37           82%
  Tronvik \[[@pone.0130733.ref067]\](2003) Norway                                           Episodic                       5.7                           Candesartan (16)                          Frequency          Parallel                 12                57            5%         43.2         79%
  **ANTICONVULSANTS**                                                                                                                                                                                                                                                                                  
  Brandes \[[@pone.0130733.ref069]\], 2004, Canada/USA                                      Episodic                       5.7                           Topiramate, (50,100,200)                  Frequency          Parallel                 26                483           46%        38.9         87%
  Cady \[[@pone.0130733.ref070]\], 2009, USA                                                Episodic                       4.4                           Carisbamate (100,300,600)                 Frequency          Parallel                 14                318           30%        41.3         85%
  de Tommaso \[[@pone.0130733.ref071]\], 2007, Italy                                        Episodic                       10.9                          Topiramate (100), Levitracetam (1000)     Frequency          Parallel                 8                 45            16%        37.8         78%
  Di' Trapani \[[@pone.0130733.ref072]\], 2000, Italy                                       Episodic                       5.2                           Gabapentin (1200)                         Frequency          Parallel                 12                63            0%         ns           52%
  Diener \[[@pone.0130733.ref073]\], 2004 Europe                                            Episodic                       5.1                           Topiramate (100, 200) Propranolol (160)   Frequency          Parallel                 20                568           37%        40.8         80%
  Edwards \[[@pone.0130733.ref075]\], 2003, USA                                             Episodic                       4.5                           Topiramate (200)                          Frequency          Parallel                 4                 70            0%         41.4         97%
  Freitag \[[@pone.0130733.ref076]\], 2002,USA                                              Episodic                       4.2                           Divalproex (1000)                         Frequency          Parallel                 12                237           15%        40.5         79%
  Ghose\[[@pone.0130733.ref077]\], 2002, New Zealand                                        Episodic (74%) Chronic (26%)   7.6                           Vigabatrin (2000)                         Frequency          Crossover (4)            12                23            17%        43.6         74%
  Gupta \[[@pone.0130733.ref078]\], 2007, India                                             Episodic                       7.0                           Topiramate (50), Lamotrigene (50)         Frequency          Crossover ()             4                 60            7%         30           78%
  Hering \[[@pone.0130733.ref079]\],1992. Israel                                            Episodic                       7.7                           Valproate (800)                           Frequency          Crossover (0)            8                 32            9%         34           79%
  Jensen \[[@pone.0130733.ref080]\],1994, Denmark                                           Episodic                       6.6                           Valproate (1500)                          Frequency          Crossover (4)            12                43            21%        46           86%
  Klapper \[[@pone.0130733.ref081]\],1997, USA                                              Episodic                       5.0                           Divalproex (500,100,1500)                 Frequency          Parallel                 12                176           22%        40.8         89%
  Lipton \[[@pone.0130733.ref082]\], 2011, USA                                              Episodic                       11.7                          Topiramate (100)                          Frequency          Parallel                 26                385           14%        40.3         89%
  Mathew \[[@pone.0130733.ref083]\], 1995, USA                                              Episodic                       6.2                           Valproate (750)                           Frequency          Parallel                 12                107           16%        45.6         78%
  Mathew \[[@pone.0130733.ref043]\], 2001,USA                                               Episodic                       4.9                           Gabapentin (2400)                         Frequency          Parallel                 12                143           39%        40           83%
  Rompel \[[@pone.0130733.ref085]\], 1970, S Africa                                         Episodic                       3.0                           Carbamazepin (ns)                         Frequency          Crossover ()             6                 48            2%         60           69%
  Silberstein \[[@pone.0130733.ref087]\],2004, USA                                          Episodic                       5.5                           Topiramate (50,100,200)                   Frequency          Parallel                 24                487           46%        40.4         89%
  Silberstein \[[@pone.0130733.ref088]\], 2006, USA                                         Episodic                       4.9                           Topiramate (200)                          Frequency          Parallel                 20                211           27%        40.8         86%
  Silberstein \[[@pone.0130733.ref090]\], 2008, USA                                         Episodic                       3--9                          Oxcarbazepine(1200)                       Frequency          Parallel                 15                170           26%        40.5         85%
  Silberstein \[[@pone.0130733.ref091]\], 2013, USA                                         Episodic                       9.2                           Gabapentin (1200,1800,2400,3000)          Frequency          Parallel                 20                263           29%        39.3--40.6   83%
  Steiner \[[@pone.0130733.ref094]\],1997, UK                                               Episodic                       4.1                           Lamotrigine (200)                         Frequency          Parallel                 12                77            31%        37.2         82%
  Stensrud \[[@pone.0130733.ref095]\],1979, Norway                                          Episodic                       6.3                           Clonazepam (1)                            Frequency          Crossover ()             4                 38            11%        ns           71%
  Storey \[[@pone.0130733.ref096]\],2001, USA                                               Episodic                       4.7                           Topiramate (200)                          Frequency          Parallel                 16                40            13%        38.3         98%
  Vahedi \[[@pone.0130733.ref097]\],2002, France                                            Episodic                       5.0                           Acetazolamide (500)                       Frequency          Parallel                 12                53            34%        39.2         75%
  Verma\[[@pone.0130733.ref098]\], 2013, India                                              Episodic                       5.7                           Levetiracetam                             Frequency          Parallel                 12                65            20%        31.1         73%
  **Beta Blockers**                                                                                                                                                                                                                                                                                    
  Ahuja\[[@pone.0130733.ref100]\], 1985, India                                              Episodic                       7.2                           Propranolol (120)                         Frequency          Crossover                8                 26            ns         ns           46%
  Al-Qassab \[[@pone.0130733.ref101]\], 1993, UK                                            Episodic                       4                             Propranolol (80, 160)                     Frequency          Crossover                8                 45            33%        36           80%
  Andersson \[[@pone.0130733.ref102]\], 1983, Denmark                                       Episodic                       4.9                           Metoprolol (200)                          Frequency          Parallel                 8                 71            13%        39.6         85%
  Borgesen \[[@pone.0130733.ref103]\], 1974, Denmark                                        Episodic                       1.8                           Propranolol (120)                         Frequency          Crossover                12                45            33%        37.6         83%
  Briggs \[[@pone.0130733.ref104]\], 1979, UK                                               Episodic                       6.9                           Tomolol (20)                              Frequency          Crossover                6                 24            4%         ns           71%
  Dahlof \[[@pone.0130733.ref105]\], 1987, Sweden                                           Episodic                       4.3                           Propranolol (120)                         Frequency          Crossover                4                 29            0%         ns           83%
  Diener \[[@pone.0130733.ref106]\], 1996, Germany                                          Episodic                       4                             Propranolol (120) Clyclandelate (1200)    Duration           Parallel                 20                214           19%        39           78%
  Diener \[[@pone.0130733.ref073]\], 2004, Germany                                          Episodic                       5.1                           Propranolol (160)                         Frequency          Parallel                 20                568           37%        40.8         80%
  Ekbom \[[@pone.0130733.ref107]\], 1972, Sweden                                            Episodic                       11.7                          Pindolol (7.5, 15)                        Frequency          Parallel                 4                 30            13%        33.7         87%
  Ekbom \[[@pone.0130733.ref108]\], 1975, Sweden                                            Episodic                       2.2                           Alprenolol (400)                          Frequency          Parallel                 6                 33            15%        41.3         82%
  Ekbom \[[@pone.0130733.ref109]\],1977, Sweden                                             Episodic                       \>3                           Oxprenolol                                Headache Index     Crossover (1)            12                34            46%        41.8         89%
  Forssman \[[@pone.0130733.ref110]\], 1976, Sweden                                         Episodic                       6.9                           Propranolol (240)                         Frequency          Crossover                12                40            20%        37.4         97%
  Forssman \[[@pone.0130733.ref111]\], 1983, Sweden                                         Episodic                       \>3                           Atenolol (100)                            Frequency          Crossover                12                24            17%        40           80%
  Freitag \[[@pone.0130733.ref112]\], 1984, USA                                             Unclear                        ns                            Nadolol (160, 240)                        Frequency          Parallel                 ns                32            ns         ns           81%
  Holroyd \[[@pone.0130733.ref113]\], 2010, USA                                             Episodic                       5.4                           Propranolol (180)                         Frequency          Parallel                 64                232 (35%)     35%        38.2         78%
  Johannsson \[[@pone.0130733.ref114]\], 1987, Sweden                                       Episodic                       \>2                           Atenolol (100)                            Frequency          Crossover                12                Ns            14%        43           70%
  Johnson \[[@pone.0130733.ref115]\], 1986, New Zealand                                     Episodic                       5                             Propranolol (240)                         Frequency          Crossover                12                29            41%        42           69%
  Kangasniemi \[[@pone.0130733.ref116]\], 1987, Norway                                      Episodic                       4.3                           Metoprolol (200)                          Frequency          Crossover (4)            8                 74            1%         37.5         79%
  Langohr \[[@pone.0130733.ref175]\],1985, Germany                                          Episodic                                                     Propranolol () Clomipramine (             Frequency          Crossover (4)            12                36            43%        44           74%
  Malvea \[[@pone.0130733.ref117]\], 1973, USA                                              Episodic                       \>4                           Propranolol (?)                           Headache Index     Crossover                6                 31            6%         ns           87%
  Mathew \[[@pone.0130733.ref118]\], 1981, USA                                              Unclear                        ns                            Propranolol (75)Amitriptyline (75)        Headache Index     Parallel                 24                554           22%        38           95%
  Mikkelsen \[[@pone.0130733.ref119]\], 1986, Denmark                                       Episodic                       \>3                           Propranolol (120)                         Frequency          Crossover (0)            12                39            21%        ns           84%
  Nadelmann \[[@pone.0130733.ref120]\], 1986, USA                                           Unclear                        ns                            Propranolol (240)                         Headache Index     Crossover (0)            6                 64            36%        ns           86%
  Nanda \[[@pone.0130733.ref121]\], 1977, Scotland                                          Episodic                       4.8                           Acebutolol (800)                          Frequency          Crossover (4)            12                43            24%        ns           74%
  Pita \[[@pone.0130733.ref123]\], 1977, Spain                                              Episodic                       5.5                           Propranolol (160)                         Headache Index     Crossover (0)            8                 9             11%        32           78%
  Pradalier \[[@pone.0130733.ref124]\], 1989, France                                        Episodic                       6.1                           Propranolol (160)                         Frequency          Parallel                 12                74            25%        37.5         76%
  Sargent \[[@pone.0130733.ref125]\], 1985, USA                                             Episodic                       \>2                           Propranolol (120)                         Frequency          Parallel                 16                161           13%        30           79%
  Sjaastad \[[@pone.0130733.ref126]\], 1972, Norway                                         Episodic                       7.5                           Pindolol (7.5)                            Frequency          Crossover (3)            4                 24            17%        35.3         75%
  Standnes \[[@pone.0130733.ref127]\], 1982, Norway,                                        Episodic                       6.7                           Propranolol (160) Timolol (20)            Frequency          Crossover                0                 25            28%        ns           80%
  Steiner \[[@pone.0130733.ref128]\], 1988, UK                                              Episodic                       4                             Metoprolol (100)                          Frequency          Parallel                 8                 59            19%        37.6         76%
  Stellar \[[@pone.0130733.ref129]\], 1984, USA                                             Episodic                       6.8                           Timolol (30)                              Frequency          Crossover                6                 107           8%         43           72%
  Stensrud \[[@pone.0130733.ref130]\], 1976, Norway                                         Episodic                       6.1                           Propranolol (160)Inderal (160)            Headache Index     Crossover (1)            4                 20            5%         ns           70%
  Stensrud \[[@pone.0130733.ref131]\], 1980, Norway                                         Episodic (n = 21)              \<15\>15                      Atenolol (100)Propranolol (160)           Frequency          Crossover (1)            6                 21            20%        ns           69%
  Tfelt-Hansen \[[@pone.0130733.ref132]\], 1984, Scandinavia                                Episodic                       6.0                           Timolol (20)Propranolol(160)              Frequency          Crossover (2)            10                96            10%        39.5         74.5%
  Van de Ven \[[@pone.0130733.ref133]\], 1997, Denmark                                      Episodic                       5.5                           Bisoprolol (10)                           Frequency          Parallel                 8                 226           14%        38.7         82%
  Weber \[[@pone.0130733.ref134]\], 1972, USA                                               Unclear                        ns                            Propranolol (80)                          Headache Index     Crossover (0)            12                25            24%        40.5         52%
  Wideroe \[[@pone.0130733.ref135]\], 1974, Norway                                          Episodic                       3                             Propranolol (160)                         Headache Index     Crossover (0)            12                30            13%        38           87%
  Zeigler \[[@pone.0130733.ref136]\], 1987, USA                                             Episodic                       2--12                         Propranolol (240)                         Headache Index     Crossover (4)            4                 30            ns         38           73%
  **Calcium Channel Blockers**                                                                                                                                                                                                                                                                         
  Nimodipine European Migraine (with aura) Trial \[[@pone.0130733.ref137]\], 1989, EU       Episodic                       3.3                           Nimodipine (120)                          Frequency          Parallel                 12                89            19%        33.8         79%
  Nimodipine European Migraine (Without aura) trial (1989) \[[@pone.0130733.ref138]\], EU   Episodic                       4.4                           Nimodipine (120)                          Frequency          Parallel                 12                192           16%        38.1         78%
  Ansell \[[@pone.0130733.ref139]\], 1988, UK                                               Episodic                       \>2                           Nimodipine (120)                          Headache Index     Parallel                 12                68            16%        ns           71%
  Gelmers \[[@pone.0130733.ref140]\], 1983, Netherlands                                     Episodic                       9.1                           Nimodipine (120)                          Headache Index     Parallel                 12                60            17%        30           62%
  Havanka-Kanniainen \[[@pone.0130733.ref141]\], 1985, Finland                              Episodic                       7.9                           Nimodipine (120)                          Frequency          Crossover (0)            8                 33            12%        33           85%
  Leandri \[[@pone.0130733.ref142]\], 1990, Italy                                           Episodic                       4.3                           Nicardipine (40)                          Frequency          Crossover (ns)           8                 35            15%        ns           ns
  Markley \[[@pone.0130733.ref143]\], 1984, USA                                             Episodic                       3.4                           Verapamil (240)                           Frequency          Crossover (ns)           8                 20            30%        33           86%
  McArthur \[[@pone.0130733.ref144]\], 1989, USA                                            Episodic                       2.3                           Nifedipine (90)                           Frequency          Crossover (1)            12                24            42%        ns           ns
  Shukla \[[@pone.0130733.ref145]\], 1995, UK                                               Episodic                       10.4                          Nifedipine (15)                           Frequency          Crossover (ns)           6                 36            22%        22.8         50%
  Solomon \[[@pone.0130733.ref146]\], 1983, USA                                             Episodic                       6.7                           Verapamil (320)                           Frequency          Crossover (ns)           6                 12            52%        38           78%
  Stewart \[[@pone.0130733.ref147]\], 1988, Canada                                          Episodic                       6.3                           Nimodipine (120)                          Frequency          Parallel                 8                 37            19%        ns           ns
  **Flunarizine**                                                                                                                                                                                                                                                                                      
  Diamond \[[@pone.0130733.ref148]\], 1992, USA                                             Episodic                       4.3                           Flunarizine (10)                          Frequency          Parallel                 20                143           8%         34.8         74%
  Frenken \[[@pone.0130733.ref149]\], 1984, Netherlands                                     Episodic                       3.6                           Flunarizine (10)                          Frequency          Parallel                 12                35            0%         NS           83%
  Louis \[[@pone.0130733.ref150]\], 1981, Belgium                                           Episodic                       1.2                           Flunarizine (10)                          Frequency          Parallel                 12                58            0%         29           50%
  Mendenopoulos \[[@pone.0130733.ref151]\], 1985, Greece                                    Episodic                       4                             Flunarizine (10)                          Headache Index     Parallel                 12                20            0%         44           80%
  Pini \[[@pone.0130733.ref152]\], 1986, Italy                                              Episodic                       9.9                           Flunarizine (20)                          Headache Index     Parallel                 4                 18            0%         40.2         83%
  Sorensen \[[@pone.0130733.ref153]\], 1986, Denmark                                        Episodic                       3                             Flunarizine (10)                          Frequency          Crossover (4)            16                29            7%         40           79%
  Thomas \[[@pone.0130733.ref154]\], 1991, India                                            Episodic                       6.7                           Flunarizine (10)                          Headache Index     Crossover (2)            12                29            48%        30.5         87%
  **Selective Serotonin Reuptake Inhibitor**                                                                                                                                                                                                                                                           
  Adly \[[@pone.0130733.ref155]\], 1993, USA.                                               Episodic                       \>4                           Fluoxetine (40)                           Headache Index     Parallel                 10                32            44%        37.5         83%
  d\'Amato \[[@pone.0130733.ref156]\], 1999, Italy.                                         Episodic                       1--4                          Fluoxetine (20)                           Headache Index     Parallel                 20                52            0%         37.6         63%
  Landy \[[@pone.0130733.ref157]\], 1998, USA.                                              Episodic                       \>2                           Sertraline (50)                           Headache Index     Parallel                 8                 27            41%        36           93%
  Steiner \[[@pone.0130733.ref159]\], 1998, UK.                                             Episodic                       3.9                           s-Fluoxetine (40)                         Frequency          Parallel                 12                53            32%        37           75%
  Zeeberg \[[@pone.0130733.ref160]\], 1981, Sweden                                          Episodic                       3.5                           Femoxitine (300)                          Headache Index     Parallel                 12                59            ns         ns           ns
  **Serotonin Norepinephrine Reuptake Inhibitor**                                                                                                                                                                                                                                                      
  Ozyalcin \[[@pone.0130733.ref161]\], 2004, Turkey                                         Episodic                       2.3                           Venlafaxine (75, 150)                     Frequency          Parallel                 8                 60            17%        36.5         83%
  **Serotonin Agonist**                                                                                                                                                                                                                                                                                
  Arthur \[[@pone.0130733.ref162]\], 1971, New Zealand                                      Episodic                       8.1                           Pizotifen (3.0)                           Frequency          Crossover (ns)           4                 63            17%        ns           ns
  Bellavance \[[@pone.0130733.ref163]\], 1990, Canada                                       Episodic                       6.7                           Pizotifen (1.5)                           Frequency          Parallel                 12                176           14%        32.5         79%
  Carroll \[[@pone.0130733.ref164]\], 1975, UK                                              Episodic                       \>3                           Pizotifen (3.0)                           Headache Index     Crossover (2)            4                 27            48%        ns           ns
  Cleland \[[@pone.0130733.ref165]\], 1997, UK                                              Episodic                       3.4                           Pizotifen (2.0)                           Frequency          Crossover (ns)           12                130           32%        40.5         63%
  Hughes \[[@pone.0130733.ref166]\], 1971, UK                                               Episodic                       9.1                           Pizotifen (0.5)                           Frequency          Crossover (ns)           12                26            0%         ns           81%
  Kangasniemi \[[@pone.0130733.ref167]\], 1979, Finland                                     Episodic                       4.3                           Pizotifen (1.5)                           Frequency          Crossover (0)            7                 50            22%        36           80%
  Lance, 1968                                                                                                                                            Pizotifen                                                                                                                                     
  Lawrence \[[@pone.0130733.ref168]\], 1977, UK                                             Episodic                       \>4                           Pizotifen (1.5)                           Headache Index     Parallel                 12                36            14%        ns           79%
  Osterman \[[@pone.0130733.ref169]\], 1977, Sweden                                         Episodic                       5.1                           Pizotifen (0.5)                           Frequency          Crossover (2)            8                 30            10%        37           70%
  Ryan \[[@pone.0130733.ref170]\], 1968, USA                                                Episodic                       8.9                           Pizotifen (4)                             Frequency          Crossover (ns)           4                 62            ns         ns           ns
  **Tricyclic Antidepressants**                                                                                                                                                                                                                                                                        
  Couch \[[@pone.0130733.ref241]\], 1976, USA                                               Episodic                       6.9                           Amitriptyline (100)                       Headache Index     Parallel                 4                 73            36%        NS           64%
  Couch \[[@pone.0130733.ref171]\], 1979                                                    Episodic                       6.9                           Amitriptyline (100)                       Frequency          Parallel                 8                 162           38%        NS           85%
  Couch \[[@pone.0130733.ref172]\], 2011, USA                                               Episodic                       7.6                           Amitriptyline (100)                       Frequency          Parallel                 16                391           51%        34.9         81%
  Gomersall \[[@pone.0130733.ref173]\], 1973, UK                                            Episodic                       2.7                           Amitriptyline (60)                        Frequency          Crossover (0)            26                20            20%        42           75%
  Jacobs \[[@pone.0130733.ref174]\], 1972, UK                                               Episodic                       3.3                           Opipramol (75)                            Frequency          Parallel                 12                27            43%        42           78%
  Langohr \[[@pone.0130733.ref175]\], 1985, Germany                                         Episodic                       \>4                           Clomipramine (100)                        Frequency          Crossover (4)            4                 36            43%        44           67%
  Mathew \[[@pone.0130733.ref118]\], 1981, USA                                              Unclear                        Unclear                       Amitriptyline (75)                        Headache Index     Parallel                 24                554           22%        38           95%
  Noone \[[@pone.0130733.ref177]\], 1980, UK                                                Episodic                       6                             Clomipramine (30)                         Frequency          Crossover                4                 10            50%        Ns           70%
  Ziegler \[[@pone.0130733.ref136]\], 1987, USA                                             Episodic                       2--12                         Amitriptyline (100)                       Headache Index     Crossover (1)            8                 30            0%         38           73%

10.1371/journal.pone.0130733.t003

###### Study characteristics of included randomized trials of treatment of chronic (≥15 headaches/month) migraine headaches.
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  ----------------------------------------------------- --------------------------------------------- ---------- ---------------------------------- ---------------- --------------- ---- ----- ----- ------ -----
  **Alpha Blocker**                                                                                                                                                                                          
  Saper \[[@pone.0130733.ref059]\], 2002, USA           Chronic                                       ns         Tizanidine (24)                    Headache Index   Parallel        12   136   32%   40     79%
  **Anticonvulsant**                                                                                                                                                                                         
  Diener \[[@pone.0130733.ref074]\], 2007, Italy        Chronic                                       15.9       Topiramate (100)                   Frequency        Parallel        24   59    36%   46.1   75%
  Mei \[[@pone.0130733.ref084]\], 2006, Italy           Chronic                                       24         Topiramate (100)                   Frequency        Parallel        12   50    42%   45.8   69%
  Silberstein \[[@pone.0130733.ref089]\], 2007, USA     Chronic                                       17.0       Topiramate (100)                   Frequency        Parallel        16   306   46%   38.2   85%
  Silvestrini \[[@pone.0130733.ref092]\], 2003, Italy   Chronic                                       20         Topiramate (50)                    Frequency        Parallel        8    28    0%    43.5   64%
  Yurekli, 2008, Turkey                                 Chronic                                       22         Valproate (1000)                   Frequency        Parallel        12   29    9%    40.4   83%
  **Beta-Blockers**                                                                                                                                                                                          
  Palferman \[[@pone.0130733.ref122]\], 1983, UK        Chronic                                       12.1       Propranolol (120)                  Frequency        Crossover(?)    8    22    39%   37.8   73%
  Stensrud \[[@pone.0130733.ref131]\], 1980, Norway     Chronic                                       \>15       Atenolol (100) Propranolol (160)   Frequency        Crossover (1)   6    7     20%   ns     69%
  **Chronic Daily Headache (\>15 Headaches/Month)**                                                                                                                                                          
  **Anticonvulsants**                                                                                                                                                                                        
  Beran\[[@pone.0130733.ref068]\], 2010, Australia      Chronic Daily Headache                        19.6       Levetiracetam (3000)               Frequency        Crossover (1)   11   96    30%   48.8   53%
  Sarchielli \[[@pone.0130733.ref086]\], 2014, Italy    Chronic Daily Headache (Medication overuse)   21.8       Valproate (800)                    Frequency        Parallel        24   88    17%   ns     90%
  Spira \[[@pone.0130733.ref093]\], 2003,Australia      Chronic Daily Headache                        27.4       Gabapentin (2400)                  Frequency        Crossover (1)   8    133   17%   43     69%
  Yurekli \[[@pone.0130733.ref099]\], 2008, Turkey      Chronic Daily                                 22.7       Valproate (1000)                   Frequency        Parallel        12   29    0%    40.4   83%
  **Selective Serotonin Reuptake Inhibitor**                                                                                                                                                                 
  Saper \[[@pone.0130733.ref158]\], 1994, USA           Chronic Daily                                 \>16       Fluoxetine (40)                    Frequency        Parallel        12   111   5     36.5   87%
  Stensrud \[[@pone.0130733.ref131]\], 1980, Norway     Episodic (n = 21)Chronic (n = 7)              \<15\>15   Atenolol (100) Propranolol (160)   Frequency        Crossover (1)   6    35    20%   ns     69%
  ----------------------------------------------------- --------------------------------------------- ---------- ---------------------------------- ---------------- --------------- ---- ----- ----- ------ -----

Overall, the studies varied in quality. Quality ratings for placebo controlled trials are given in [Table 4](#pone.0130733.t004){ref-type="table"}. By Jadad criteria, 34% of studies had scores ≤ 3.0, suggesting low quality, 39% had scores between 3 and 5 consistent with modest quality and only 37% had scores ≥ 5 suggesting high quality. Only 36% used an intention to treat analysis, 27% assessed compliance, 26% had concealed allocation, and 51% had adequate blinding. There was no difference in the overall effect sizes for placebo controlled trials using Jadad criteria as a scale (p = 0.44) or when coded as high, modest or low quality (p = 0.37), or when assessed by most of the specific Jadad or Cochrane Risk of Bias quality characteristics (compliance p = 0.59; blinding p = 0.36; adequacy of blinding p = 0.50, industry sponsorship p = 0.52; incomplete outcome reporting p = 0.96, reporting of withdrawals p = 0.24). However, trials which had inadequate concealed allocation had significantly (p = 0.02) higher reported effects (SMD: -0.52, 95% CI: -0.63 to -0.41) than those who had concealed allocation (SMD: -0.26, 95% CI: -0.34 to 0.17).

10.1371/journal.pone.0130733.t004

###### Quality Ratings of included placebo controlled trials.
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                                                                             Cochrane Risk of Bias                                                                     
  -------------------------------------------------------------------------- ----------------------- ----- --------- --------- --------- --------- --------- --------- ---------
  **EPISODIC MIGRAINES**                                                                                                                                               
  **Alpha Blockers**                                                                                                                                                   
  Adam, 1978, UK                                                             2                       No    Unclear   Unclear   Unclear   Unclear   Unclear   Unclear   No
  Boison, 1978, Sweden                                                       2                       No    Unclear   Unclear   Unclear   Unclear   Unclear   Unclear   No
  Bredfeldt, 1989, USA                                                       5                       No    Unclear   Unclear   Yes       Unclear   Unclear   Unclear   Yes
  Lynggaard, 1975, Denmark                                                   4                       No    Unclear   Unclear   Unclear   Unclear   Unclear   Unclear   Unclear
  Mondrup, 1977, Denmark                                                     6                       No    Unclear   Unclear   Yes       Unclear   Unclear   Unclear   No
  Ryan, 1975, USA                                                            1                       No    Unclear   Unclear   Unclear   Unclear   Unclear   Unclear   No
  Shafar, 1972, UK                                                           4                       No    Unclear   Unclear   Unclear   Unclear   Unclear   Unclear   Yes
  Stensrud, 1976, Norway                                                     0                       No    Unclear   Unclear   Unclear   Unclear   Unclear   Unclear   No
  **Antiogensin Enzyme Converting Inhibitors**                                                                                                                         
  Schrader (2001), Norway, Lisinopril                                        6                       Yes   Unclear   Unclear   Yes       Unclear   Unclear   Unclear   Yes
  **Angiotensin Receptor Blocker**                                                                                                                                     
  Diener (2009), Germany, Telmisartan                                        3                       No    Unclear   Unclear   Unclear   Unclear   Unclear   Unclear   Yes
  Trovnik (2003) Norway, Candesartan                                         8                       Yes   Yes       Yes       Yes       Unclear   Unclear   Unclear   Yes
  **Anticonvulsants**                                                                                                                                                  
  Brandes, 2004, Canada/USA, Topiramate                                      8                       Yes   Yes       Yes       Yes       Yes       Yes       Unclear   Yes
  Cady, 2009, USA, Carisbamate                                               8                       Yes   Yes       Yes       Yes       Unclear   Unclear   Unclear   Yes
  de Tommaso, 2007, Italy, Topiramate, Levitracetam                          4                       No    Unclear   Unclear   Unclear   Unclear   Unclear   Unclear   Unclear
  Di' Trapani, 2000, Italy, Gabapentin                                       4                       Yes   Unclear   Unclear   Unclear   Yes       Unclear   Unclear   Unclear
  Diener, 2004 Europe, Topiramate, Propropranolol                            6                       Yes   Unclear   Unclear   Unclear   Yes       Yes       Unclear   Yes
  Diener, 2007, Italy, Topiramate                                            8                       No    Yes       Yes       Yes       Yes       Unclear   Unclear   Unclear
  Edwards, 2003, USA, Topiramate                                             4                       Yes   Unclear   Unclear   Unclear   Yes       Unclear   Unclear   Yes
  Freitag, 2002, USA, divalproex                                             8                       Yes   Yes       Yes       Yes       Yes       Unclear   Unclear   Yes
  Gupta, 2007, India, Topiramate                                             8                       Yes   Yes       Yes       Yes       Yes       Unclear   No        Unclear
  Hering 1992, Israel, Valproate                                             4                       No    Unclear   Unclear   Unclear   Unclear   Unclear   Unclear   Unclear
  Jensen,1994, Denmark, Valproate                                            6                       No    Unclear   Unclear   Yes       Unclear   Unclear   Unclear   Yes
  Klapper,1997, USA, Divalproex                                              4                       Yes   Unclear   Unclear   Unclear   Unclear   Unclear   Unclear   Yes
  Lipton, 2011, USA, Topiramate                                              8                       Yes   Yes       Yes       Yes       Yes       No        Unclear   Yes
  Mathew, 1995, USA, Valproate                                               6                       No    Unclear   Unclear   Yes       Unclear   Unclear   Unclear   Yes
  Mathew, 2001, USA, Gabapentin                                              6                       Yes   Yes       Unclear   Unclear   Unclear   Unclear   Unclear   Yes
  Rompel, 1970, S Africa, Carbamazepine                                      5                       No    Yes       Yes       Yes       Yes       Yes       Unclear   Yes
  Silberstein,2004, USA, Topiramate                                          6                       Yes   Yes       Yes       Unclear   Yes       Unclear   Unclear   Yes
  Silberstein, 2006, USA, Topiramate                                         4                       Yes   Unclear   Unclear   Unclear   Unclear   Unclear   Unclear   Yes
  Silberstein, 2008, USA, Oxcarbazepine                                      8                       Yes   Yes       Yes       Yes       Yes       Unclear   Unclear   Yes
  Steiner,1997, UK, Lamotrigine                                              6                       No    Unclear   Unclear   Yes       Unclear   Unclear   Unclear   Unclear
  Stensrud,1979, Norway, Clonazepam                                          2                       No    Unclear   Unclear   Unclear   Unclear   Unclear   Unclear   Unclear
  Storey,2001, USA, Topiramate                                               4                       No    Unclear   Unclear   Unclear   Unclear   Unclear   Unclear   Yes
  Vahedi,2002, France, Acetazolamide                                         6                       Yes   Yes       Yes       Yes       Yes       Yes       Unclear   Yes
  **Beta Blockers**                                                                                                                                                    
  Ahuja, 1985, India, Propanolol                                             2                       No    Unclear   Unclear   Unclear   Unclear   Unclear   Unclear   Yes
  Al-Qassab, 1993, England, Propanolol                                       3                       No    Unclear   Unclear   Yes       Unclear   Unclear   Unclear   Yes
  Andersson, 1983, Denmark, Metoprolol                                       2                       Yes   Unclear   Unclear   Yes       No        Unclear   Unclear   Unclear
  Borgesen, 1974, Denmark, Propranolol                                       4                       No    Unclear   Unclear   Yes       No        No        No        Unclear
  Dahlof, 1987, Sweden, Propranolol                                          5                       Yes   Unclear   Unclear   Yes       No        No        No        Unclear
  Diener, 1996, Germany, Propranolol, Clyclandelate                          4                       Yes   Unclear   Unclear   Unclear   Unclear   Unclear   Unclear   Unclear
  Diener, 2004, Germany, Propranolol                                         6                       Yes   Unclear   Unclear   Unclear   Yes       Yes       Unclear   Yes
  Ekbom, 1972, Sweden, Pindolol                                              2                       No    Unclear   Unclear   Unclear   Unclear   Unclear   Unclear   Unclear
  Ekbom, 1975, Sweden, Alprenolol                                            2                       No    Unclear   Unclear   Unclear   Yes       Unclear   Unclear   Yes
  Forssman, 1976, Sweden, Propranolol                                        6                       No    Unclear   Unclear   Yes       Unclear   Unclear   Unclear   Yes
  Forssman, 1983, Sweden, Atenolol                                           2                       No    Unclear   Unclear   Unclear   Unclear   Unclear   Unclear   Yes
  Freitag, 1984, USA, Nadolol                                                3                       Yes   Unclear   Unclear   Yes       Unclear   Unclear   Unclear   Unclear
  Holroyd, 2010, USA, Propanolol                                             6                       Yes   Yes       Yes       Yes       Yes       Yes       Unclear   Unclear
  Johannsson, 1987, Sweden, Atenolol                                         2                       No    Unclear   Unclear   Unclear   Unclear   Unclear   Unclear   Unclear
  Johnson, 1986, New Zealand, Propanolol                                     3                       No    Unclear   Unclear   Yes       Unclear   Unclear   Unclear   Unclear
  Kangasniemi, 1987, Norway, Metoprolol                                      0                       4     Yes       Unclear   Unclear   Unclear   Yes       Unclear   Unclear
  Malvea, 1973, USA, Propanolol                                              4                       Yes   Unclear   Unclear   Unclear   Yes       Unclear   Unclear   Unclear
  Mathew, 1981, USA, Propanolol, Amitriptyline                               2                       No    Unclear   Unclear   No        No        No        Yes       Unclear
  Mikkelsen, 1986, Denmark, Propanolol                                       6                       No    Unclear   Unclear   Unclear   Unclear   Unclear   Unclear   Yes
  Nadelmann, 1986, USA, Propanolol                                           6                       No    Unclear   Unclear   Yes       Unclear   Unclear   Unclear   Yes
  Nanda, 1977, Scotland, Acebutolol                                          2                       No    Unclear   Unclear   Unclear   No        Unclear   Unclear   Yes
  Pita, 1977, Spain, Propranolol                                             6                       No    No        Unclear   Yes       Yes       Unclear   Unclear   Yes
  Pradalier, 1989, France, Propranolol                                       5                       Yes   Unclear   Unclear   Yes       Unclear   Unclear   Unclear   Unclear
  Sargent, 1985, USA, Propranolol                                            4                       No    Unclear   Unclear   Unclear   Unclear   Unclear   Unclear   Unclear
  Sjaastad, 1972, Norway, Pindolol                                           5                       No    Unclear   Unclear   Yes       Unclear   Unclear   Unclear   Unclear
  Standnes, 1982, Norway, Propranolol, Timolol                               4                       No    Unclear   Unclear   Yes       Unclear   Unclear   Unclear   Yes
  Steiner, 1988, UK, Metoprolol                                              6                       No    Unclear   Unclear   Yes       No        No        Unclear   Unclear
  Stellar, 1984, USA, Timolol                                                7                       No    Yes       Unclear   Yes       No        Unclear   Unclear   Unclear
  Stensrud, 1976, Norway, Propranolol, Inderal                               5                       No    Unclear   Unclear   Yes       Unclear   Unclear   Unclear   Yes
  Tfelt-Hansen, 1984, Scandinavia, Timolol, Propranolol                      6                       No    Unclear   Unclear   Yes       Unclear   Unclear   Unclear   Unclear
  Van de Ven, 1997, Denmark, Bisoprolol                                      4                       Yes   Unclear   Unclear   Unclear   Unclear   Unclear   Unclear   Unclear
  Wideroe, 1974, Norway, Propranolol                                         4                       No    Unclear   Unclear   Yes       No        Unclear   Unclear   Yes
  Zeigler, 1987, USA, Propranolol                                            3                       No    Unclear   Unclear   Yes       Yes       Unclear   Unclear   No
  **Calcium Channel Blockers**                                                                                                                                         
  Ansell, 1988, UK, Nimodipine                                               3                       No    Unclear   Unclear   Unclear   Unclear   Unclear   Unclear   Unclear
  Gelmers, 1983, Netherlands, Nimodipine                                     4                       No    Unclear   Unclear   Unclear   Unclear   Unclear   Unclear   Unclear
  Havanka-Kanniainen, 1985, Finland, Nimodipine                              4                       No    Unclear   Unclear   Unclear   Unclear   Unclear   Unclear   Yes
  Leandri, 1990, Italy, Nicardipine                                          3                       No    Unclear   Unclear   Yes       Unclear   Unclear   Unclear   Yes
  Markley, 1984, USA, Verapamil                                              3                       No    Unclear   Unclear   Unclear   Unclear   Unclear   Unclear   Unclear
  McArthur, 1989, USA, Nifedipine                                            3                       No    Unclear   Unclear   Unclear   Unclear   Unclear   Unclear   Yes
  Nimodipine European Migraine (with aura) Trial, 1989, EU, Nimodipine       2                       No    Unclear   Unclear   Unclear   Unclear   Unclear   Unclear   Unclear
  Nimodipine European Migraine (Without aura) trial (1989), EU, Nimodipine   5                       Yes   Unclear   Unclear   Yes       Unclear   Unclear   Unclear   Unclear
  Shukla, 1995, UK, Nifedipine                                               5                       No    Unclear   Unclear   Yes       Unclear   Unclear   Unclear   Unclear
  Solomon, 1983, USA, Verapamil                                              5                       No    Unclear   Unclear   Yes       No        No        Unclear   Yes
  Stewart, 1988, Canada, Nimodipine                                          2                       No    Unclear   Unclear   Unclear   Unclear   Unclear   Unclear   Unclear
  **Flunarazine**                                                                                                                                                      
  Diamond, 1993, USA,                                                        2                       No    Unclear   Unclear   Unclear   Unclear   Unclear   Unclear   Unclear
  Frenken, 1984, Netherlands, Flunarizine                                    6                       Yes   Unclear   Unclear   Yes       Yes       Unclear   Unclear   Yes
  Louis, 1981, Belgium, Flunarizine                                          5                       Yes   Unclear   Unclear   Yes       Yes       Yes       Unclear   No
  Mendenopoulos, 1985, Greece, Flunarizine                                   7                       Yes   Yes       Yes       Yes       Yes       Unclear   Unclear   Yes
  Pini, 1986, Italy, Flunarizine                                             2                       No    Unclear   Unclear   Unclear   Unclear   Unclear   Unclear   Unclear
  Sorensen, 1986, Denmark, Flunarizine                                       4                       No    Unclear   Unclear   Unclear   Unclear   Unclear   Unclear   Unclear
  Thomas, 1991, India, Flunarizine                                           3                       No    Unclear   Unclear   Yes       Unclear   Unclear   Unclear   Unclear
  **Selective Serotonin Reuptake Inhibitors**                                                                                                                          
  Adly, 1993, USA, Fluoxetine                                                2                       No    Unclear   Yes       Unclear   No        No        Unclear   Unclear
  d\'Amato, 1999, Italy, Fluoxetine                                          5                       No    Unclear   Unclear   Yes       No        No        Unclear   Unclear
  Landy, 1998, USA, Sertaline                                                3                       No    Unclear   Unclear   Unclear   No        No        Unclear   No
  Steiner, 1998, UK, s-Fluoxetine                                            6                       No    Unclear   Unclear   Yes       No        No        Unclear   Unclear
  Zeeberg, 1981, Sweden, Femoxitine                                          2                       No    No        No        No        Unclear   Unclear   Unclear   Unclear
  **Serotonin Norepinephrine Reuptake Inhibitor**                                                                                                                      
  Ozyalcin, 2004, Turkey, Venlafaxine                                        3                       No    Unclear   Unclear   Unclear   No        No        Unclear   Yes
  **Serotonin Agonist (Pizotifen)**                                                                                                                                    
  Arthur, 1971, New Zealand, Pizotifen                                       2                       No    Unclear   Unclear   Unclear   Unclear   Unclear   Unclear   Yes
  Bellavance, 1990, Canada, Pizotifen                                        4                       No    Unclear   Unclear   Unclear   Unclear   Unclear   Unclear   Unclear
  Carroll, 1975, UK, Pizotifen                                               4                       No    Unclear   Unclear   Unclear   Unclear   Unclear   Unclear   Unclear
  Cleland, 1997, UK, Pizotifen                                               4                       No    Unclear   Unclear   Unclear   Unclear   Unclear   Unclear   Unclear
  Hughes, 1971, UK, Pizotifen                                                4                       Yes   Unclear   Unclear   Unclear   Unclear   Unclear   Unclear   Unclear
  Kangasniemi, 1979, Finland, Pizotifen                                      4                       Yes   Unclear   Unclear   Unclear   Yes       Unclear   Unclear   Unclear
  Lance, 1968, Pizotifen                                                                                                                                               
  Lawrence, 1977, UK, Pizotifen                                              4                       No    Unclear   Unclear   Yes       Unclear   Unclear   Unclear   Unclear
  Osterman, 1977, Sweden, Pizotifen                                          5                       No    Unclear   Unclear   Yes       Unclear   Unclear   Unclear   Unclear
  Ryan, 1968, USA, Pizotifen                                                 5                       No    Unclear   Unclear   Unclear   Unclear   Unclear   Unclear   Unclear
  **Tricyclic Antidepressants**                                                                                                                                        
  Couch, 1976, USA, Amitriptyline                                            3                       No    Unclear   Unclear   Yes       No        Unclear   Yes       Yes
  Couch, 1979, Amitriptyline                                                 6                       No    Unclear   Unclear   Yes       No        Unclear   Unclear   Yes
  Couch, 2011, USA, Amitriptyline                                            8                       No    Yes       Yes       Yes       No        Unclear   Unclear   Yes
  Gomersall, 1973, UK, Amitriptyline                                         3                       No    Unclear   Unclear   Unclear   No        No        Yes       Yes
  Jacobs, 1972, UK, Opipramol                                                4                       No    Unclear   Yes       Yes       No        No        Yes       Yes
  Langohr, 1985, Germany, Clomipramine                                       4                       No    Unclear   Unclear   Unclear   No        No        Yes       Yes
  Morland, 1979, Norway, Doxepin                                             3                       No    Unclear   Unclear   Unclear   No        Unclear   Yes       Unclear
  Noone, 1980, UK, Clomipramin                                               4                       No    Yes       Yes       Unclear   No        Unclear   Yes       Yes
  Ziegler, 1987, USA, Amitriptyline                                          3                       No    Unclear   Unclear   Yes       Yes       Unclear   Unclear   No
  **CHRONIC MIGRAINES**                                                                                                                                                
  **Alpha-blockers**                                                                                                                                                   
  Saper, 2002, USA                                                           6                       No    Unclear   Unclear   Yes       Unclear   Unclear   Unclear   Yes
  **Anticonvulsants**                                                                                                                                                  
  Diener, 2007, Italy, Topiramate                                            8                       No    Yes       Yes       Yes       Yes       Unclear   Unclear   Unclear
  Mei, 2006, Italy, Topiramate                                               4                       Yes   Unclear   Unclear   Unclear   Unclear   Unclear   Unclear   Unclear
  Silberstein, 2007, USA, Topiramate                                         8                       Yes   Yes       Yes       Yes       Yes       Unclear   Unclear   Yes
  Silvestrini, 2003, Italy, Topiramate                                       4                       Yes   Unclear   Unclear   Unclear   Yes       Unclear   Unclear   Unclear
  **Beta Blockers**                                                                                                                                                    
  Palferman, 1983, UK, Propranolol                                           3                       No    Unclear   Unclear   Unclear   Unclear   Unclear   Unclear   Unclear
  **CHRONIC DAILY HEADACHE**                                                                                                                                           
  **Anticonvulsants**                                                                                                                                                  
  Beran, 2010, Australia, Levetiracetam                                      5                       No    Yes       Yes       Unclear   Unclear   Unclear   Unclear   Yes
  Spira, 2003, Australia, Gabapentin                                         4                       No    Unclear   Unclear   Unclear   Unclear   Unclear   Unclear   Unclear
  Yurekli, 2008, Turkey, Valproate                                           4                       No    Unclear   Unclear   Yes       Yes       Unclear   Unclear   Unclear
  **Selective Serotonin Reuptake Inhibitors**                                                                                                                          
  Saper, 1994, USA, Fluoxetine                                               8                       No    Yes       Yes       Yes       Unclear   Unclear   Unclear   Yes
  **MIXED (CHRONIC + EPISODIC)**                                                                                                                                       
  **Anticonvulsants**                                                                                                                                                  
  Ghose, 2002, New Zealand, Vigabatrin                                       4                       No    Unclear   Unclear   Unclear   Unclear   Unclear   Unclear   Unclear
  **Beta Blockers**                                                                                                                                                    
  Stensrud, 1980, Norway, Atenolol                                           5                       No    Unclear   Unclear   Yes       Unclear   Unclear   Unclear   Yes
  **Unclear Migraine Headache Type**                                                                                                                                   
  **Beta Blockers**                                                                                                                                                    
  Freitag, 1984, USA, Nadolol                                                3                       Yes   Unclear   Unclear   Yes       Unclear   Unclear   Unclear   Unclear
  Mathew, 1981, USA, Propranolol, Amitriptyline                              2                       No    Unclear   Unclear   No        No        No        Yes       Unclear
  Nadelmann, 1986, USA, Propranolol                                          6                       No    Unclear   Unclear   Yes       Unclear   Unclear   Unclear   Yes
  Weber, 1972, USA, Propranolol                                              3                       No    Unclear   Unclear   Unclear   Unclear   Unclear   Unclear   Yes
  **Selective Serotonin Reuptake Inhibitors**                                                                                                                          
  Saper, 1994, USA, Fluoxetine                                               8                       No    Yes       Yes       Yes       Unclear   Unclear   Unclear   Yes
  **Tricyclic Antidepressants**                                                                                                                                        
  Mathew, 1981, USA, Amitriptyline                                           2                       No    Unclear   Unclear   No        No        No        Yes       Unclear

### Alpha-blockers {#sec011}

There were 9 trials comparing alpha blockers to placebo with a total of 4590 participants who averaged 39.3 (range 12--76) years in age with 84% women ([Table 2](#pone.0130733.t002){ref-type="table"}). All of the studies measured headache frequency. Eight of these trials focused on episodic migraine headaches; all studied clonidine. One trial focused on chronic migraines using tizanidine. The average rate of withdrawals was 32%. Studies averaged 11 weeks (range 4--82) with a mean of 71.3 participants (range 11--67). At no time point was clonidine more effective than placebo for episodic migraines ([Table 5](#pone.0130733.t005){ref-type="table"}, [Fig 2](#pone.0130733.g002){ref-type="fig"}) and tizanidine was no more effective than placebo for chronic migraine headaches ([Table 6](#pone.0130733.t006){ref-type="table"}). None of these trials reported on the likelihood of a 50% reduction in headaches.

![Alpha blockers compared to placebo for episodic migraine headaches.](pone.0130733.g002){#pone.0130733.g002}

10.1371/journal.pone.0130733.t005

###### Placebo Controlled Randomized Clinical Trials of Continuous Outcomes among patients with episodic migraines (\<15 headaches/month).

![](pone.0130733.t005){#pone.0130733.t005g}

  Drug                                               Time Point (weeks)          Metric                            Study (Year)                 Pooled Mean Difference (95% CI)              Heterogeneity
  -------------------------------------------------- --------------------------- --------------------------------- ---------------------------- -------------------------------------------- ---------------------------------
  **Alpha Blockers**                                                                                                                                                                         
  Clonidine                                          8                           Headaches/month                   Boisen (1978)                -0.09 (-0.99 to 0.80)                        
  8                                                  Headaches/month             Bredfeldt (1989)                  -0.96 (-2.6 to 0.64)                                                      
  8                                                  Headaches/month             Ryan (1975)                       -0.46 (-2.7 to 1.8)                                                       
  8                                                  Headaches/month             Shafar (1972)                     -0.72 (-1.6 to 0.14)                                                      
  8                                                  Headaches/month             Stensrud (1976)                   -1.0 (-3.1 to 1.1)                                                        
  8                                                                              **Pooled (HA/Month):**            **-0.52 (-1.06 to 0.02)**    Q = 1.57, df = 4, I^2^ = 0.0%                
  12                                                 Headaches/month             Lynggaard (1975)                  -0.37 (-3.4 to 2.)                                                        
  12                                                 Headaches/month             Mondrup (1977)                    1.1 (-2.5 to 4.8)                                                         
  12                                                                             **Pooled (HA/Month):**            **0.24 (-2.1 to 2.6)**       Q = 0.38, df = 1, I^2^ = 0.0%                
  24                                                 Headaches/month             Adam (1978)                       0.00 (-0.47 to 0.47)                                                      
  **Angiotensin Converting Enzyme Inhibitors**                                                                                                                                               
  Enalapril                                          4                           Headaches/month                   Sonbolestan (2013)           -2.4 (-7.5 to 2.7)                           
  Enalapril                                          8                           Headaches/month                   Sonbolestan (2013)           -0.83 (-6.2 to 4.5)                          
  Lisinopril                                         12                          Headaches/month                   Schrader (2001)              -1.4 (-2.6 to -0.2)                          
  Captopril                                          16                          Headache Index                    Paterna (1992)               -0.86 (-1.5 to -0.21)                        
  **Angiotensin Receptor Blockers**                                                                                                                                                          
  Candesaran                                         12                          Headaches/month                   Stovner (2013)               -0.58 (-1.4 to 0.23)                         
  12                                                 Headaches/month             Trovnik (2003)                    -1.6 (-3.0 to -0.16)                                                      
  12                                                                             **Pooled (HA/Month)**             **-0.9 (-1.8 to 0.03)**      Q = 1.46, df = 1, I^2^ = 31.7%               
  Telmisartan                                        12                          Headaches/month                   Diener (2009)                -1.9 (-3.6 to -0.23)                         ---
  12                                                                             **Pooled (HA/Month)**             **-1.1 (-1.9 to -0.27)**     **Q = 2.82, df = 3 I** ^**2**^ **= 29.1%**   
  **Anticonvulsants**                                                                                                                                                                        
  Acetazolamide                                      12                          Headaches/month                   Vahedi (2002)                0.5 (-1.7 to 2.7)                            
  Carbamazipine                                      6                           Headaches/month                   Rompel (1970)                -3.2 (-6.6 to 0.20)                          
  Carisbamate                                        14                          Headaches/month                   Cady (2009)                  -0.09 (-0.34 to 0.17)                        
  Clonazepam                                         4                           Headaches/month                   Stensrud (1979)              -3.6 (-7.2 to 0.03))                         
  Gabapentin                                         4                           Headaches/month                   Di'Trapani                   -0.2 (-1.6 to 1.2)                           
  8                                                  Headaches/month             Di"Trapani                        -1.1 (-2.5 to 0.34)                                                       
  12                                                 Headaches/month             Di' Trapani (2000)                -1.9 (-3.4 to -0.41)                                                      
  12                                                 Headaches/month             Mathew (2001)                     -0.2 (-0.89 to 0.49)                                                      
  12                                                                             **Pooled (HA/Month)**             ---**0.92 (-2.6 to 0.74)**   Q = 4.1, df = 2, I2 = 75.6%                  
  20                                                 Headaches/month             Silberstein (2013)                -0.33 (-0.71 to 0.04)                                                     
  Lamotrigine                                        4                           Headaches/month                   Gupta (2006)                 -1.2 (-2.2 to -0.18)                         
  12                                                 Headaches/month             Steiner (1997)                    0.20 (-0.36 to 0.76)                                                      
  Levetiracetam                                      8                           Headaches/month                   De Tommaso (2007)            -4.2 (-7.2 to -1.3)                          
  12                                                 Headaches/month             Verma (2013)                      -2.2 (-3.0 to -1.3)                                                       
                                                                                 **Pooled (HA/Month)**             -2.7 (-4.4 to -0.97)         Q = 1.69, df = 1 I^2^ = 40.9%                
  Oxcarbazepine                                      15                          Headaches/month                   Silberstein (2008)           0.17 (-0.13 to 0.47)                         
  Topiramate                                         4 (50 mg/day)               Headaches/month                   Brandes (2004)               -0.75 (-1.4 to -0.06)                        
  4 (50 mg/day)                                      Headaches/month             Gupta (2006)                      -2.1 (-3.0 to -1.1)                                                       
  4 (50 mg/day)                                      Headaches/month             Silberstein (2004)                -1.0 (-1.9 to-- 0.13)                                                     
  4 (50 mg/day)                                      Headaches/month             Silvestrini (2003)                -5.0 (-9.2 to -0.8)                                                       
  4 (50 mg/day)                                                                  **Pooled (HA/Month)**             **-1.4 (-2.2 to -0.5)**      Q = 7.81, df = 3, I^2^ = 43.0%               
  Topiramate                                         4 (100 mg/day)              Headaches/month                   Brandes (2004)               -0.80 (-1.4 to -0.18)                        
                                                     4 (100 mg/day)              Headaches/month                   Diener (2004)                -1.1 (-1.9 to -0.2)                          
                                                     4 (100 mg/day)              Headaches/month                   Silberstein (2004)           -0.9 (-1.7 to -0.14)                         
                                                     4 (100 mg/day)                                                **Pooled (HA/Month)**        **-0.89 (-1.3 to -0.48)**                    Q = 0.23, df = 2, I2 = 0.0%
                                                     4 (200 mg/day)              Headaches/month                   Brandes (2004)               -1.9 (-2.4 to -1.3)                          
                                                     4 (200 mg/day)              Headaches/month                   Edwards (2003)               -0.60 (-1.1 to -0.13)                        
                                                     4 (200 mg/day)              Headaches/month                   Silberstein (2004)           -1.4 (-2.2 to -0.62)                         
                                                     4 (200 mg/day)              Headaches/month                   Silberstein (2006)           -0.9 (-2.3 to 0.55)                          
                                                     4 (200 mg/day)                                                **Pooled (HA/Month)**        **-0.91 (-1.3 to -0.48)**                    Q = 12.07, df = 3 I2 = 75.1%
                                                     **4 (all doses)**                                             **Pooled (HA/Month)**        -1.1 (-1.5 to-0.79)                          Q = 21.3, df = 10, I^2^ = 53%
                                                     8 (50 mg/day)               Headaches/month                   Brandes (2004)               -0.50 (01.2 to 0.19)                         
                                                     8 (50 mg/day)               Headaches/month                   Silberstein (2004)           -0.80 (-1.4 to -0.20)                        
                                                     8 (50 mg/day)               Headaches/month                   Silberstein (2006)           -12.5 (-17.1 to -7.9)                        
                                                     8 (50 mg/day)               Headaches/month                   **Pooled (HA/Month)**        **-2.3 (-4.4 to -0.23)**                     Q = 25.56, df = 2, I^2^ = 92.2%
                                                     8 (100 mg/day)              Headaches/month                   Brandes (2004)               -0.8 (-1.4 to -0.18)                         
                                                     8 (100 mg/day)              Headaches/month                   De Tammosa (2007)            -5.2 (-7.8 to -2.5)                          
                                                     8 (100 mg/day)              Headaches/month                   Diener (2004)                -0.85 (-2.1 to 0.39)                         
                                                     8 (100 mg/day)              Headaches/month                   Silberstein (2004)           -1.1 (-1.7 to -0.53)                         
                                                     8 (100 mg/day)                                                **Pooled (HA/Month)**        **-1.3 (-2.2 to -0.43)**                     Q = 10.18, df = 3, I^2^70.5%
                                                     8 (200 mg/day)              Headaches/month                   Brandes (2004)               -1.8 (-2.3 to -1.3)                          
                                                     8 (200 mg/day)              Headaches/month                   Silberstein (2004)           -1.5 (-2.1 to -0.9)                          
                                                     8 (200 mg/day)              Headaches/month                   Silberstein (2006)           -0.30 (-1.7 to 1.1)                          
                                                     8 (200 mg/day)                                                **Pooled (HA/Month)**        **-1.5 (-2.1 to -0.87)**                     Q = 3.68, df = 2, I^2^ = 45.7%
                                                     8 (All Doses)                                                 **Pooled (HA/Month)**        **-1.3 (-1.9 to -0.7)**                      Q = 46.42, df = 9, I^2^ = 80.6%
                                                     12 (50 mg/day)              Headaches/month                   Brandes (2004)               -0.40 (-1.1 to 0.29)                         
                                                     12 (50 mg/day)              Headaches/month                   Silberstein (2004)           -0.70 (-1.4 to 0.02)                         
                                                     12 (50 mg/day)                                                **Pooled (HA/Month):**       **-0.54 (-1.0 to -0.05)**                    Q = 0.39, df = 2, I^2^ = 0.0%
                                                     12 (100 mg/day)             Headaches/month                   Brandes (2004)               -0.75 (-1.4 to -0.13)                        
                                                     12 (100 mg/day)             Headaches/month                   Diener (2004)                -0.90 (-2.2 to 0.39)                         
                                                     12 (100 mg/day)             Headaches/month                   Silberstein (2004)           -1.1 (-2.0 to -0.19)                         
                                                     12 (100 mg/day)                                               **Pooled (HA/Month):**       **-0.87 (-1.3 to -0.39)**                    Q = 1.52, df = 2, I^2^ = 0.0%
                                                     12 (200 mg/day)             Headaches/month                   Brandes (2004)               -1.7 (-2.2 to -1.1)                          
                                                     12 (200 mg/day)             Headaches/month                   Silberstein (2004)           -1.4 (-2.2 to -0.59)                         
                                                     12 (200 mg/day)             Headaches/month                   Silberstein (2006)           -0.70 (-2.1 to 0.75)                         
                                                     12 (200 mg/day)                                               **Pooled (HA/Month):**       **-1.5 (-1.9 to -1.1)**                      Q = 0.35, df = 1, I^2^ = 0.0%
                                                     **12 (All doses)**                                            **Pooled (HA/Month):**       **-0.99 (-1.3 to -0.64)**                    Q = 0.04, df = 1, I^2^ = 0.0%
                                                     16 (50 mg/day)              Headaches/month                   Brandes (2004)               -0.50 (-1.2 to 0.19)                         
                                                     16 (50 mg/day)              Headaches/month                   Silberstein (2004)           -0.40 (-1.1 to 0.33)                         
                                                     16 (50 mg/day)                                                **Pooled (HA/Month):**       **-0.45 (-0.95 to 0.05)**                    Q = 0.04, df = 1, I^2^ = 0.0%
                                                     16 (100 mg/day)             Headaches/month                   Brandes (2004)               -0.70 (-1.3 to -0.08)                        
                                                     16 (100 mg/day)             Headaches/month                   Diener (2004)                -1.1 (-2.4 to 0.24)                          
                                                     16 (100 mg/day)             Headaches/month                   Silberstein (2004)           -1.2 (-2.0 to -0.38)                         
                                                     16 (100 mg/day)             Headaches/month                   Silberstein (2007)           -1.5 (-3.1 to 0.06)                          
                                                     16 (100 mg/day)                                               **Pooled (HA/Month):**       **-0.95 (-1.4 to -0.51)**                    Q = 1.51, df = 3, I^2^ = 0.0%
                                                     16 (200 mg/day)             Headaches/month                   Brandes (2004)               -1.6 (-2.1 to -1.1)                          
                                                     16 (200 mg/day)             Headaches/month                   Silberstein (2004)           -1.3 (-2.2 to -0.45)                         
                                                     16 (200 mg/day)             Headaches/month                   Silberstein (2006)           -0.05 (-1.5 to 1.4)                          
                                                     16 (200 mg/day)             Headaches/month                   Storey (2001)                -0.52 (-1.67 to 0.63)                        
                                                     16 (200 mg/day)                                               **Pooled (HA/Month):**       **-1.0 (-1.7 to -0.44)**                     Q = 5.76, df = 3, I^2^ = 47.9%
                                                     **16 (All doses)**                                            **Pooled (HA/Month):**       **-0.92 (-1.2 to -0.59)**                    Q = 13.41, df = 9, I^2^ = 32.9%
                                                     20 (50mg/day)               Headaches/month                   Brandes (2004)               -0.50 (-1.2 to 0.19)                         
                                                     20 (50mg/day)               Headaches/month                   Silberstein (2004)           -0.55 (-1.5 to 0.40)                         
                                                     20 (50mg/day)                                                 **Pooled (HA/Month):**       **-0.52 (-1.1 to 0.04)**                     Q = 0.01, df = 1, I^2^ = 0.0%
                                                     20 (100 mg/day)             Headaches/month                   Brandes (2004)               -0.70 (-1.3 to -0.08)                        
  20 (100 mg/day)                                    Headaches/month             Diener (2004)                     -1.2 (-2.6 to 0.17)                                                       
  20 (100 mg/day)                                    Headaches/month             Silberstein (2004)                -1.4 (-2.3 to -0.39)                                                      
  20 (100 mg/day)                                                                **Pooled (HA/Month):**            **-0.93 (-1.4 to -0.44)**    Q = 1.42, df = 2, I^2^ = 0.0%                
  20 (200 mg/day)                                    Headaches/month             Brandes (2004)                    -1.5 (-2.0 to -0.95)                                                      
  20 (200 mg/day)                                    Headaches/month             Silberstein (2004)                -1.4 (-2.3 to -0.36)                                                      
  20 (200 mg/day)                                    Headaches/month             Silberstein (2006)                -0.50 (-1.9 to 0.95)                                                      
  20 (200 mg/day)                                                                **Pooled (HA/Month):**            **-1.4 (-1.8 to 0.92)**      Q = 1.61, df = 2, I^2^ = 0.0%                
  20 (all doses)                                                                 **Pooled (HA/Month):**            **-0.98 (-1.3 to -0.66)**    Q = 8.52, df = 7, I^2^ = 17.8%               
  24 (50 mgday)                                      Headaches/month             Brandes (2004)                    -0.40 (-1.2 to 0.44)                                                      
  24 (50 mgday)                                      Headaches/month             Silberstein (2004)                -0.50 (-1.5 to 0.48)                                                      
  24 (50 mgday)                                                                  **Pooled (HA/Month):**            **-0.44 (-1.1 to 0.20)**     Q = 0.02, df = 1, I^2^ = 0.0%                
  24 (100 mg/day)                                    Headaches/month             Brandes (2004)                    -1.0 (-1.8 to -0.18)                                                      
  24 (100 mg/day)                                    Headaches/month             Lipton (2011)                     -1.4 (-2.2 to -0.60)                                                      
  24 (100 mg/day)                                    Headaches/month             Silberstein (2004)                -1.3 (-2.3 to -0.34)                                                      
  24 (100 mg/day)                                                                **Pooled (HA/Month):**            **-1.2 (-1.7 to -0.74)**     Q = 0.49, df = 2, I^2^ = 0.0%                
  24 (200 mg/day)                                    Headaches/month             Brandes (2004)                    -1.5 (-2.2 to -0.84)                                                      
  24 (200 mg/day)                                    Headaches/month             Silberstein (2004)                -1.3 (-2.3 to -0.31)                                                      
  24 (200 mg/day)                                                                **Pooled (HA/Month):**            **-1.4 (-2.0 to -0.89)**     Q = 0.11, df = 1, I^2^ = 0.0%                
  **24 (All doses)**                                                             **Pooled (HA/Month):**            **-1.1 (-1.4 to -0.77)**     Q = 6.4, df = 6, I^2^ = 6.4%                 
  Valproate                                          4                           Headaches/month                   Freitag (2002)               -0.20 (-0.61 to 0.21)                        
  4                                                  Headaches/month             Klapper (1997)                    -1.8 (-2.6 to -0.95)                                                      
  4                                                  Headaches/month             Mathew (1995                      -1.8 (-3.6 to -0.03)                                                      
  4                                                                              **Pooled (HA/Month):**            **-1.4 (-2.2 to -0.56)**     Q = 14.48, df = 2, I^2^ = 51.6%              
  8                                                  Headaches/month             Freitag (2002)                    -0.25 (-0.51 to 0.01)                                                     
  8                                                  Headaches/month             Hering (1992)                     -6.8 (-12.10 to -1.5)                                                     
  8                                                  Headaches/month             Klapper (1997)                    -1.6 (-2.3 to -0.95)                                                      
  8                                                  Headaches/month             Mathew (1995)                     -2.1 (-3.6 to -0.56)                                                      
  8                                                                              **Pooled (HA/Month):**            **-1.5 (-2.2 to -0.76)**     Q = 17.35, df = 3. I^2^ = 42.6%              
  12                                                 Headaches/month             Freitag (2002)                    -0.45 (-0.86 to -0.04)                                                    
  12                                                 Headaches/month             Jensen (1994)                     -2.6 (-5.5 to 0.26)                                                       
  12                                                 Headaches/month             Klapper (1997)                    -1.7 (-2.4 to -0.96)                                                      
  12                                                 Headaches/month             Mathew (1995)                     -2.8 (-4.8 to -0.74)                                                      
  12                                                                             **Pooled (HA/Month):**            **-1.5 (-2.1 to -0.80)**     Q = 24.7, I^2^ = 63.6%                       
  Vigabatrin                                         4                           Headaches/month                   Ghose (2002)                 -0.54 (-1.9 to 0.77)                         
  8                                                  Headaches/month             Ghose (2002)                      -0.27 (-2.3 to 1.7)                                                       
  12                                                 Headaches/month             Ghose (2002)                      -0.42 (-2.3 to 1.6)                                                       
  **Beta-Blockers**                                                                                                                                                                          
  Acebutolol                                         4                           Headaches/month                   Nanda (1977)                 0.10 (-0.75 to 0.95)                         
  8                                                  Headaches/month             Nanda (1977)                      -0.50 (-1.35 to 0.35)                                                     
  12                                                 Headaches/month             Nanda (1977)                      -0.68 (-1.68 to 0.32)                                                     
  Alprenolol                                         8                           Headaches/month                   Ekbom (1975)                 0.20 (-0.91 to 1.3)                          
  Atenolol                                           8                           Headaches/month                   Stensrud (1980)              -1.5 (-3.0 to -0.04)                         
  12                                                 Headaches/month             Forssman (1983)                   -5.4 (-12.6 to 1.8)                                                       
  12                                                 Headaches/month             Johansson (1987)                  -2.05 (-3.76to -0.48)                                                     
  12                                                                             **Pooled SMD**                    **-2.2 (-3.7 to -0.67)**     Q = 0.80, df = 1, I^2^ = 0.0%                
  Bisoprolol                                         4                           Headaches/month                   Van de Ven (1997)            -0.40 (-0.87 to 0.07)                        
  8                                                  Headaches/month             Van de Ven (1997)                 -0.61 (-1.1 to -0.16)                                                     
  Metoprolol                                         4                           Headaches/month                   Langor (1985)                -0.63 (-1.5 to 0.25)                         
  8                                                  Headaches/month             Andersson (1983)                  -1.5 (-2.4 to -0.60)                                                      
  8                                                  Headaches/month             Kangasniemi (1987)                -0.70 (-1.4 to -0.03)                                                     
  8                                                  Headaches/month             Steiner (1987)                    -0.80 (-1.7 to 0.13)                                                      
  8                                                                              **Pooled HA/Month**               **-0.94 (-1.4 to -0.46)**    Q = 1.02, I^2^ = 0.0%                        
  Oxprenolol                                         8                           Headaches/month                   Ekbom (1977)                 -080 (-3.9 to 2.3)                           
  Pindolol                                           4                           Headaches/month                   Ekbom (1972)                 2.9 (-1.0 to 6.8)                            
  4                                                  Headaches/month             Sjaastad (1972)                   1.5 (-5.5 to 2.6)                                                         
  4                                                                              **Pooled HA/Month**               **1.2 (-2.5 to 4.9)**        Q = 0.49, I^2^ = 0.0%                        
  Propranolol                                        4                           Headaches/month                   Dahlof (1987)                -1.1 (-2.2 to 0.05)                          
  4                                                  Headaches/month             Diener (2004)                     -1.1 (-1.9 to -0.28)                                                      
  4                                                  Headaches/month             Pradalier (1989)                  -1.5 (-2.1 to -0.87)                                                      
  4                                                  Headaches/month             Stensrud (1976)                   -1.1 (-3.5 to 1.3)                                                        
  4                                                                              **Pooled HA/Month**               **-1.1 (-1.5 to -0.74)**     Q = 3.44, df = 3, I^2^ = 0.00%               
  4                                                  Headache Index              Zeigler (1987)                    -0.68 (-1.4 to 0.06)                                                      
  8                                                  Headaches/month             Ahuja (1985)                      -5.9 (-11.4 to -0.37)                                                     
  8                                                  Headaches/month             Al-Qassab (1993)                  0.6 (-2.84 to 4.0)                                                        
  8                                                  Headaches/month             Diener (2004)                     -0.8 (-1.6 to -0.005)                                                     
  8                                                  Headaches/month             Holroyd (2010)                    -0.6 (-1.3 to 0.12)                                                       
  8                                                  Headaches/month             Pita (1977)                       -5.3 (-8.7 to -1.8)                                                       
  8                                                                              **Pooled HA/Month**               **-1.0 (-2.1 to -0.39)**     Q = 11.08, df = 4, I^2^ = 54.9%              
  8                                                  Headache index              Nadelmann (1986)                  -0.54 (-1.11 to 0.04)                                                     
  12                                                 Headaches/month             Borgesen (1974)                   -0.30 (-1.1 to -0.48)                                                     
  12                                                 Headaches/month             Diener (2004)                     -0.80 (-1.6 to -0.02)                                                     
  12                                                 Headaches/month             Forssman (1976)                   -1.8 (-3.9 to 0.4)                                                        
  12                                                 Headaches/month             Holroyd (2010)                    -0.8 (-1.5 to -0.08)                                                      
  12                                                 Headaches/month             Johnson (1986)                    -6.3 (-16.6 to 3.9)                                                       
  12                                                 Headaches/month             Mikkelsen (1986)                  -2.4 (-7.9 to 3.1)                                                        
  12                                                 Headaches/month             Pradalier (1989)                  -3.3 (-3.9 to -2.6)                                                       
  12                                                 Headaches/month             Standnes (1982)                   -1.4 (-2.7 to -0.12)                                                      
  12                                                 Headaches/month             Stovner (2013)                    -0.62 (-1.4 to 0.16)                                                      
  12                                                 Headaches/month             Tfelt-Hansen (1983)               -1.2 (-2.8 to 0.45)                                                       
  12                                                 Headaches/month             Wideroe (1974)                    -1.3 (-1.8 to -0.78)                                                      
  12                                                                             **Pooled HA/Month**               **-1.3 (-2.0 to -0.62)**     Q = 46.35, df = 10, I^2^ = 78.4%             
  12                                                 Headache hours/month        Diener (1996)                     -12.9 (-31.8 to 5.9)                                                      
  16                                                 Headaches/month             Diener (2004)                     -1.1 (-2.2 to -0.01)                                                      
  16                                                 Headaches/month             Holroyd (2010)                    -0.90 (-2.6 to -0.19)                                                     
  16                                                 Headaches/month             Sargent (1985)                    0.5 (-0.22 to 1.2)                                                        
                                                                                 **Pooled HA/Month**               **-0.46 (-1.5 to 0.57)**     Q = 9.40, df = 2, I^2^ = 78.7%               
  20                                                 Headaches/month             Diener (2004)                     -1.5(-2.9 to -0.03)                                                       
  20                                                 Headaches/month             Holroyd (2010)                    -0.9 (-1.6 to -0.18)                                                      
  20                                                                             **Pooled HA/Month**               **-1.0 (-1.7 to -0.37)**     Q = 0.52, df = 1, I^2^ = 0.0%                
  Tomolol                                            8                           Headaches/month                   Briggs (1979                 -2.3 (-5.2 to 0.63)                          
  8                                                  Headaches/month             Stellar (1984)                    -0.70 (-1.5 to 0.07)                                                      
  8                                                                              **Pooled HA/Month**               **-0.85 (-1.8 to 0.07)**     Q = 1.01, df = 1, I^2^ = 6.8%                
  12                                                 Headaches/month             Standnes (1982)                   -1.9 (-3.2 to -0.54)                                                      
  12                                                 Headaches/month             Tfelt-Hansen (1984)               -1.5 (-3.0 to 0.05)                                                       
  12                                                 Headaches/month             **Pooled HA/Month**               **-1.7 (-2.7 to -0.70)**     Q = 0.12, df = 1, I^2^ = 0.0%                
  **Calcium Channel Blockers**                                                                                                                                                               
  Cyclendelate                                       12                          Headache duration/month (hours)   Diener (1996)                15.0 hours (-5.3 to 35.3)                    
  Nicardipine                                        8                           Headaches/month                   Leandri (1990)               -1.6 (-3.3 to 0.15)                          
  Nifedipine                                         4                           Headaches/month                   McArthur (1989)              -0.20 (-0.72 to 0.32)                        
  4                                                  Headaches/month             Shukla (1995)                     -3.8 (-4.8 to -2.8)                                                       
  4                                                                              **Pooled HA/Month**               **-2.0 (-5.5 to 1.6)**       Q = 2.92, df = 1, I^2^ = 65.8%               
  8                                                  Headaches/month             McArthur (1989)                   -0.20 (-0.72 to 0.32)                                                     
  12                                                 Headaches/month             McArthur (1989)                   -0.40 (-1.4 to 0.66)                                                      
  Nimodipine                                         4                           Headaches/month                   Gelmers (1983)               -0.13 (-0.64 to 0.38)                        
  4                                                  Headaches/month             MINES (1989)                      0.48 (-0.47 to 0.46)                                                      
  4                                                  Headaches/month             MINES (1989)                      0.10 (-0.21 to 0.41)                                                      
  4                                                  Headaches/month             Stewart (1988)                    -0.31 (-3.3 to 2.7)                                                       
  4                                                                              **Pooled HA/Month**               **-0.07 (-0.28 to 0.13)**    Q = 1.51, df = 3, I^2^ = 0.0%                
  4                                                  Headache Index              Ansell (1988)                     -0.36 (-0.88 to 0.16)                                                     
  8                                                  Headaches/month             Gelmers (1983)                    -1.5 (-2.4 to -0.73)                                                      
  8                                                  Headaches/month             Havanka (1985)                    -2.2 (-4.2 to -0.24)                                                      
  8                                                  Headaches/month             MINES (1989)                      0.17 (-0.54 to 0.88)                                                      
  8                                                  Headaches/month             MINES (1989)                      0.94 (-0.45 to 2.32)                                                      
  8                                                  Headaches/month             Stewart (1988)                    -3.4 (-5.7 to -1.1)                                                       
  8                                                                              **Pooled HA/Month**               **-0.98 (-2.3 to 0.30)**     Q = 22.35, df = 4, I^2^ = 82.1%              
  8                                                  Headache Index              Ansell (1988)                     -0.48 (-1.01 to 0.05)                                                     
  12                                                 Headaches/month             Gelmers (1983)                    -1.3 (-1.9 to -0.69)                                                      
  12                                                 Headaches/month             MINES (1989)                      0.74 (0.03 to 1.5)                                                        
  12                                                 Headaches/month             MINES (1989)                      -0.01 (-1.4 to 1.4)                                                       
  12                                                 Headaches/month             Stewart (1988)                    -2.8 (-5.2 to -0.48)                                                      
  12                                                                             **Pooled HA/Month**               **-0.65 (-2.0 to 0.74)**     Q = 22.41,df-, I^2^ = 86.6%                  
                                                     12                          Headache Index                    Ansell (1988)                0.16 (-0.36 to 0.68)                         
  Verapamil                                          4                           Headaches/month                   Solomon (1983)               -2.9 (-7.8 to 1.9)                           
  8                                                  Headaches/month             Markley (1984)                    -0.60 (-1.4 to 0.19)                                                      
  **Flunarizine**                                                                                                                                                                            
  Flunarizine                                        4                           Headaches/month                   Diamond (1993)               0.60 (-0.35 to 0.47)                         
  4                                                  Headaches/month             Frenken (1984)                    -1.3 (-2.4 to -0.24)                                                      
  4                                                                              **Pooled Ha/Month**               **-0.53 (-1.8 to 0.79)**     Q = 5.51, df = 1, I^2^ = 81.9%               
  4                                                  Headache Index              Mendenopoulos (1985)              -0.63 (1.5 to 0.27)                                                       
  4                                                  Headache Index              Pini (1986)                       0.19 (-0.73 to 1.1)                                                       
  4                                                  Headache Index              **Pooled SMD**                    **-0.23 (-1.0 to 0.58)**     Q = 1.56, df = 1, I^2^ = 35.8%               
  4                                                                              **Overall Pooled SMD**            **-0.27 (-0.76 to 0.23)**    Q = 6.15, df = 3, I^2^ = 51.2%               
  8                                                  Headaches/month             Diamond (1993)                    -0.44 (-1.7 to 0.78)                                                      
  8                                                  Headaches/month             Frenken (1984)                    -1.9 (-3.5 to -0.31)                                                      
  8                                                                              **Pooled Ha/Month**               **-1.1 (-2.5 to 0.34)**      Q = 2.04, df = 1, I^2^ = 51.1%               
  8                                                  Headache Index              Mendenopoulos (1985)              -1.2 (-2.1 to -0.2)                                                       
  8                                                                              **Overall Pooled SMD**            **-0.60 (-1.2 to 0.005)**    Q = 4.92, df = 2, I^2^ = 59.3%               
  12                                                 Headaches/month             Diamond (1993)                    -0.61 (-1.8 to 0.65)                                                      
  12                                                 Headaches/month             Frenken (1984)                    -1.8 (-3.3 to -0.38)                                                      
  12                                                 Headaches/month             Louis (1981)                      -1.1 (-1.7 to -0.6)                                                       
  12                                                                             **Pooled Ha/Month**               **-1.1 (-1.6 to -0.67)**     Q = 1.39, df = 2, I^2^ = 0.0%                
  12                                                 Headache Index              Mendenopoulos (1985)              -1.6 (-2.6 to -0.6)                                                       
  12                                                 Headache Index              Thomas (1989)                     -0.87 (2.0 to 0.24)                                                       
  12                                                 Headache Index              **Pooled SMD**                    **-1.3 (-2.0 to -0.52)**     Q = 0.94, df = 1, I^2^ = 0.0%                
  12                                                                             **Overall Pooled SMD**            **-0.84 (-1.3 to -0.34)**    Q = 10.33, df = 4, I^2^ = 61.3%              
  16                                                 Headaches/month             Diamond (1993)                    -1.2 (-2.1 to -0.24)                                                      
  16                                                 Headaches/month             Sorensen (1986)                   -1.2 (-2.7 to 0.37)                                                       
  16                                                                             **Pooled Ha/Month**               **-1.2 (-2.0 to -0.38)**                                                  
  20                                                 Headaches/month             Diamond (1993)                    -0.36 (-2.4 to 1.69)                                                      
  **Selective Serotonin Reuptake Inhibitors**                                                                                                                                                
                                                     4                           Headaches/month                   Orholm (1986)                -0.20 (-1.3 to 0.93)                         
                                                     4                           Headaches/month                   Zeeberg (1981                0.00 (-1.8 to 1.8)                           
  Femoxitine                                         4                                                             **Pooled Ha/Month**          **-0.14 (-1.1 to 0.81)**                     Q = 0.03, df = 1, I^2^ = 0.0%
  8                                                  Headaches/month             Orholm (1986)                     -0.10 (-1.2 to 1.0)                                                       
  8                                                  Headaches/month             Zeeberg (1981)                    -1.8 (-3.6 to -0.04)                                                      
  8                                                                              **Pooled Ha/Month**               ---**0.81 (-2.5 to 0.83)**   Q = 2.53, df-1, I^2^ = 60.4%                 
  12                                                 Headaches/month             Orholm (1986)                     0.50 (-0.63 to 1.6)                                                       
  12                                                 Headaches/month             Zeeberg (1981)                    -1.4 (-3.2 to 0.36)                                                       
  12                                                                             **Pooled Ha/Month**               **-0.33 (-2.2 to 1.5)**      Q = 3.16, df = 1, I^2^ = 68.3%               
  16                                                 Headaches/month             Orholm (1986)                     0.30 (-0.83 to 1.4)                                                       
  Fluoxetine                                         4                           Headache index                    Adly (1993)                  -0.34 (-1.27 to 0.59)                        
  4                                                  Headache index              d'Amato (1999)                    -0.08 (-0.63 to 0.48)                                                     
  4                                                  Headaches/month             Steiner (1998)                    -0.71 (-1.36 to -0.06)                                                    
  4                                                                              **Pooled SMD**                    **-0.35 (-0.75 to 0.05)**    Q = 2.11, df = 3, I^2^ = 5.2%                
  8                                                  Headache index              Adly (1993)                       -0.74 (-1.70 to 0.22)                                                     
  8                                                  Headache index              d'Amato (1999)                    -0.01 (-0.56 to 0.55)                                                     
  8                                                  Headaches/month             Steiner (1998)                    -0.32 (-0.98 to 0.35)                                                     
  8                                                                              **Pooled SMD**                    **-0.23 (-0.63 to 0.16)**    Q = 1.76, I^2^ = 0.0%                        
  12                                                 Headache index              Adly (1993)                       -1.02 (-2.01 to -0.03)                                                    
  12                                                 Headache index              d'Amato (1999)                    -0.32 (-0.88 to 0.24)                                                     
  12                                                 Headaches/month             Steiner (1998)                    -0.74 (-1.44 to -0.03)                                                    
  12                                                                             **Pooled SMD**                    **-0.57 (-0.97 to -0.17)**   Q = 1.77, df = 2, I^2^ = 0.0%                
  16                                                 Headache index              d'Amato (1999)                    -0.64 (-1.22 to -0.07)                                                    
  20                                                 Headache index              d'Amato (1999)                    -0.32 (-0.88 to 0.24)                                                     
  Sertraline                                         4                           Headache index                    Landy (1999)                 0.44 (-0.59 to 1.5)                          
                                                     8                           Headache index                    Landy (1988)                 0.08 (-0.94 to 1.09)                         
  **Pooled SMD (12 weeks)**                          **-0.35 (-0.75 to 0.05)**   Q = 7.49, df = 4, I^22^ = 46.6%                                                                             
  **Serotonin Norepinephrine Reuptake Inhibitors**                                                                                                                                           
  Venlafaxine                                        8                           Headaches/month                   Ozyalcin (2004)              -2.0 (-4.0 to -0.06)                         
  **Serotonin Antagonist**                                                                                                                                                                   
  Pizotifen                                          4                           Headaches/month                   Arthur (1971)                -0.51 (-1.07 to 0.05)                        
  4                                                  Headaches/month             Ryan (1968)                       -0.36 (-0.86 to 0.15)                                                     
  4                                                                              **Pooled HA/month**               **-0.42 (-0.80 to -0.05)**   Q = 0.16m df = 1, I^2^ = 0.0%                
  4                                                  Headache index              Carroll (1975)                    0.18 (-0.87 to 1.23)                                                      
  4                                                  Headache index              Lawrence (1977)                   -0.04 (-0.78 to 0.70)                                                     
  4                                                                              **Pooled SMD**                    **-0.15 (-0.47 to 0.17)**    Q = 6.40, df = 1, I^2^ = 0.0%                
  4                                                                              **Overall Pooled SMD**            **-0.30 (-0.62 to 0.02)**    Q = 6.40, df = 7, I^2^ = 0.0%                
  8                                                  Headaches/month             Kangasniemi (1979)                -0.57 (-1.26 to 0.12)                                                     
  8                                                  Headaches/month             Osterman (1977)                   -0.63 (-1.4 to 0.1)                                                       
  8                                                                              **Pooled HA/month**               **-0.60 (-1.1 to -0.08)**    Q = 0.01, df = 1, I^2^ = 0.0%                
  8                                                  Headache index              Lawrence (1977)                   -0.56 (-1.32 to 0.20)                                                     
  8                                                                              **Overall Pooled SMD**            **-0.48 (-0.85 to -0.12)**   Q = 1.37, df = 4, I^2^ = 0.0%                
  12                                                 Headaches/month             Bellavance (1990)                 -0.49 (-0.86 to -0.12)                                                    
  12                                                 Headaches/month             Cleland (1997)                    -0.41 (-0.83 to 0.14)                                                     
  12                                                 Headaches/month             Hughes (1971)                     -0.26 (-1.03 to 0.52)                                                     
  12                                                                             **Pooled HA/month**               **-0.43 (-0.66 to -0.21)**   Q = 0.30, df = 2, I^2^ = 0.0%                
  12                                                 Headache index              Lawrence (1977)                   -0.56 (-1.32 to 0.20)                                                     
                                                                                 **Overall Pooled SMD**            **-0.44 (-0.69 to -0.20)**   Q = 0.48, df = 5, I^2^ = 0.0%                
  **Tricyclic Antidepressants**                                                                                                                                                              
  Amitriptyline                                      4                           Headache index                    Couch (2011)                 -0.34 (-0.62 to -0.05)                       
  4                                                  Headache index              Zeigler (1987)                    -0.52 (-1.25 to 0.21)                                                     
  4                                                                              **Pooled SMD**                    **-0.57 (-0.92 to -0.23)**   Q = 0.08, df = 1, I^2^ = 0.0%                
  24                                                 Headaches/month             Gomersall (1973)                  -1.29 (-1.79 to -0.46)                                                    
  24                                                 Headache index              Mathew (1981)                     -1.31 (-1.85 to -0.77)                                                    
  24                                                                             **Pooled SMD**                    **-1.2 (-1.7 to -0.82)**     Q = 0.35, df = 2, I^2^ = 0.0%                
  Clomipramine                                       4                           Headaches/month                   Langohr (1985)               0.10 (-1.2 to 1.01)                          
  4                                                  Headaches/month             Loldrup (1989)                    -0.51 (-0.81 to -0.20)                                                    
  4                                                  Headaches/month             Noone (1980)                      -0.3 (-1.19 to 0.58)                                                      
  4                                                                              **Pooled SMD**                    **-0.46 (-0.74 to -0.18)**                                                
  Doxepin                                            4                           Headache index                    Morland (1979)               -0.77 (-1.54 to 0.00)                        ---
  Opipramol                                          4                           Headaches/month                   Jacobs (1972)                -1.2 (-2.1 to -0.3)                          
  12                                                                             Jacobs (1972)                     -1.3 (-2.5 to -0.12)                                                      

SMD: Standardized Mean Difference
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###### Placebo controlled comparisons of continuous outcomes among patients with chronic migraine headache (≥ 15 headaches/month).
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  ---------------------------------------------------- ----------------- ------------------------ --------------------------- -------------------------------- -----
  **Chronic Daily Headache**                                                                                                                                   
  Fluoxetine                                           12                Headaches/month          Saper (1994)                -0.40 (-1.1 to 0.35)             ---
  Gabapentin                                           8                 Headaches/month          Spira (2003)                -2.7 (-5.2 to 0.28)              ---
  Levetiracetam                                        82                Headaches/month          Beran (2010)                -3.6 (-7.7 to 0.56)              ---
  **Chronic Migraines (15 or more headaches/month)**                                                                                                           
  Atenolol                                             6                 Headaches/month          Stensrud (1980)             0.32 (-0.73 to 1.38)             ---
  Propranolol                                          8                 Headaches/month          Palferman (1988)            -0.70 (-1.3 to -0.09)            
  6                                                    Headaches/month   Stensrud (1980)          0.24 (-0.82 to 1.29)                                         
                                                                         **Pooled SMD**           **-0.34 (-1.23 to 0.56)**   Q = 0.13, df = 2, I^2^ = 56.1%   
  Tizanidine                                           4                 Headaches/month          Saper (2002)                -1.1 (---2.4 to 0.16)            ---
  8                                                    Headaches/month   Saper (2002)             -1.0 (-2.3 to 0.30)         ---                              
  12                                                   Headaches/month   Saper (2002)             -0.50 (-1.6 to 0.62)        ---                              
  Topiramate                                           4                 Headaches/month          Diener (2007)               -4.9 (-7.7 to -2.1)              
  4                                                    Headaches/month   Mei (2006)               -9.2 (-15.7 to -2.7)                                         
  4                                                    Headaches/month   Silvestrini (2003)       -5.0 (-9.2 to -0.81)                                         
  4                                                                      **Pooled (HA/Month)**    **-5.4 (-7.6 to -3.2)**     Q = 0.34, df = 2, I^2^ = 0.0%    
  8                                                    Headaches/month   Diener (2007)            -3.1 (-5.9 to -0.29)                                         
  8                                                    Headaches/month   Mei (2006)               -12.7 (-10.2 to -6.2)                                        
  8                                                    Headaches/month   Silvestrini (2003)       -12.5 (-17.1 to -7.9)                                        
                                                                         **Pooled (HA/Month):**   **-9.1 (-16.3 to -1.9)**    Q = 9.33, df = 2, I^2^ = 78.6%   
  12                                                   Headaches/month   Diener (2007)            -6.0 (-8.8 to -3.2)                                          
  12                                                   Headaches/month   Mei (2006)               -12.2 (-18.7 to -5.7)                                        
                                                                         **Pooled (HA/Month):**   **-8.4 (-14.3 to -2.5)**    Q = 0.81, df = 1, I^2^ = 0.0%    
  16                                                                     Diener (2007)            -7.6 (-10.4 to -4.8)                                         
  Valproate                                            4                 Headaches/month          Yurekli (2008)              -12.6 (-17.9 to -7.3)            
  12                                                   Headaches/month   Sarchelli (2014)         -4.3 (-7.1 to -1.5)                                          
  12                                                   Headaches/month   Yurekli (2008)           -14.3 (-19.5 to -9.1)                                        
  12                                                                     **Pooled (HA/Month):**   **-10.9 (-18.5 to -3.4)**   Q = 26.2, df = 1, I^2^ = 92.4%   
  ---------------------------------------------------- ----------------- ------------------------ --------------------------- -------------------------------- -----

### Angiotensin Converting Enzyme Inhibitors (ACE)/ Angiotensin Receptor Blockers (ARB) {#sec012}

There were three ACE (captopril, enalapril, lisinopril) and three ARB (candesartan x2, telmisartan) placebo-controlled trials, all focusing on episodic migraines ([Table 2](#pone.0130733.t002){ref-type="table"}). The ACE studies were 8, 12 and 16 weeks in duration with 120 participants who averaged 7.3 headaches per month. All three ARB studies were 12 weeks in duration with a total of 231 participants, averaging 6.5 headaches/month. One of the ACE trials suggested no benefit at 4 or 8 weeks (enalapril), another found benefit at 12 weeks (lisinopril) and a third benefit at 16 weeks (captopril, [Table 5](#pone.0130733.t005){ref-type="table"}, [Fig 3](#pone.0130733.g003){ref-type="fig"}); none of the trials reported outcomes at a common time-point. At twelve weeks, ARBs were better than placebo in reducing the frequency of headaches ([Table 5](#pone.0130733.t005){ref-type="table"}, [Fig 3](#pone.0130733.g003){ref-type="fig"}). The likelihood of experiencing at least 50% improvement was not reported in all clinical trials. One of the ACE trials (captopril) was more likely than placebo to achieve at least a 50% reduction in headache frequency ([Table 7](#pone.0130733.t007){ref-type="table"}). This was not found in the trial studying lisinopril or for two of the ARB trials.

![ACE and ARBs compared to placebo for episodic migraine headaches.](pone.0130733.g003){#pone.0130733.g003}

10.1371/journal.pone.0130733.t007

###### Placebo controlled comparisons of \>50% improvement in episodic migraine headaches (\<15 migraines/month).

![](pone.0130733.t007){#pone.0130733.t007g}

  Drug                                           Time Point (weeks)    Study (Year)            RR (95% CI)                       Heterogeneity
  ---------------------------------------------- --------------------- ----------------------- --------------------------------- ------------------------------
  **Angiotensin Converting Enzyme Inhibitors**                                                                                   
  Captopril                                      8                     Sonbolestan (2013)      5.6 (1.4--21.9)                   
  Lisinopril                                     12                    Schrader (2012)         0.82 (0.46--1.5)                  
  **Angiotensin Receptor Blockers**                                                                                              
  Candesartan                                    12                    Tronvik (2003)          18.0 (2.5--130.4)                 
  Telmisartan                                    12                    Diemer (2009)           1.6 (0.85--3.0)                   
                                                 12                    **Pooled RR**           **4.4 (0.43--46.2)**              Q = 5.2, df = 1 I^2^ = 80.8%
  **Anticonvulsants**                                                                                                            
  Acetazolamide                                  12                    Vahedi (2002)           0.92 (0.42--2.0)                  
  Carisbamate                                    12                    Cady (2009)             0.75 (0.58--0.98)                 
  Lamotrigine                                    4                     Gupta (2006)            1.4 (0.86--2.2)                   
  12                                             Steiner (1997)        0.20 (-0.36 to 0.76)                                      
  Levetiracetam                                  12                    Verma (2003)            1.4 (0.86--2.4)                   
  Oxcarbazepine                                  15                    Silberstein (2008)      0.90 (0.59--1.4)                  
  Topiramate                                     4                     Edwards (2003)          4.2 (1.3--13.7)                   
  4                                              Gupta (2006)          2.1 (1.3--3.2)                                            
  4                                              **Pooled RR:**        **2.4 (1.3--4.2)**      Q = 11.27, df = 1, I^2^ = 21.0%   
  12                                             Silberstein (2006)    1.2 (0.8--1.7)                                            
  16                                             Silberstein (2004)    2.1 (1.6--2.7)                                            
  16                                             Silberstein (2009)    1.3 (0.9--2.0)                                            
  16                                             **Pooled RR:**        **1.9 (1.4--2.5)**      Q = 6.4, df = 1, I^2^ = 52.9%     
  26                                             Brandes (2004)        1.7 (1.3--2.2)                                            
  26                                             Diener (2004)         1.6 (1.1--2.4)                                            
  26                                             **Pooled RR:**        **1.8 (1.5--2.2)**      Q = 1.72, df = 1, I^2^ = 0.0%     
  26                                             Freitag (2002)        1.2 (0.8--1.9)                                            
  Valproate                                      12                    Jensen (1994)           2.8 (1.3--6.3)                    
  12                                             Klapper (1997)        2.3 (1.6--3.3)                                            
  12                                             Mathew (1995)         3.6 (1.5--8.4)                                            
  12                                             **Pooled RR**         **2.1 (1.5--3.0)**      Q = 9.1, df = 3, I^2^ = 45.1%     
  **Beta-blockers**                                                                                                              
  Propranolol                                    4                     Stensrud (1976)         1.25 (0.55--2.8)                  
  8                                              Pita (1977)           17.0 (1.0--281.9)                                         
  8                                              Zeigler (1993)        2.5 (0.65--9.7)                                           
  8                                              **Pooled RR:**        **4.3 (0.79--23.6)**    Q = 1.45, df = 1, I^2^ = 31.1%    
  12                                             Telt-Hansen (1984)    2.0 (1.2--2.8)                                            
  12                                             Weber (1972)          7.5 (1.9--28.4)                                           
  12                                             Wideroe (1974)        2.2 (1.4--3.4)                                            
  12                                             **Pooled RR:**        **2.1 (1.6--2.9)**      Q = 4.2, df = 2, I^2^ = 52.2%     
  24                                             Diener (1996)         1.4 (0.9--2.2)                                            
  26                                             Diener (2004)         2.0 (1.4--2.9)                                            
  Metoprolol                                     4                     Langohr (1985)          1.2 (0.86--1.5)                   
  Timolol                                        8                     Stellar (1984)          1.6 (1.1--2.4)                    
  12                                             Tfelt-Hansen (1984)   1.9 (1.4--2.5)                                            
  **Calcium Channel Blockers**                                                                                                   
  Cinnarizine                                    4                     Togha (2007)            0.98 (0.74--1.3)                  
  Cyclendalate                                   24                    Diener (1996)           1.3 (0.8--2.1)                    
  Flunarizine                                    12                    Thomas (1991)           2.5 (0.6--10.9)                   
  16                                             Bunoso (1998)         0.99 (0.72--1.4)                                          
  16                                             Diener (2002)         1.0 (0.88--1.2)                                           
  16                                             **Pooled RR:**        **1.02 (00.91--1.1)**   Q = 1.6, df = 1, I^2^ = 82.4%     
  Nifedipine                                     24                    Albers (1989)           0.45 (0.21--0.95)                 
  Fluoxetine                                     4                     Singh (2002)            4.5 (1.1--18.8)                   
  12                                             Saper (1994)          1.0 (0.57--1.8)                                           
  **Tricyclic Antidepressants**                                                                                                  
  Amitriptyline                                  4                     Couch (1976)            2.2 (1.0--4.8)                    
  4                                              Couch (1979)          1.60 (1.0--2.5)                                           
  4                                              **Pooled RR:**        **1.7 (1.2--2.6)**      Q = 0.54,df = 1, I^2^ = 0.0%      
  8                                              Nelson (1998)         2.22 (1.3--3.9)                                           
  8                                              Zeigler (1993)        0.83 (0.43--1.6)                                          
  8                                              **Pooled RR:**        **1.1 (0.6--2.0)**      Q = 0.64,df = 1, I^2^ = 3.0%      
  12                                             Canepari (1985))      1.60 (0.31--3.1)                                          
  26                                             Dodick (2009)         0.82 (0.61--1.1)                                          
  Clomipramine                                   4                     Langohr (1985)          0.94 (0.53--1.7)                  
  **Tetracyclic**                                                                                                                
  Maprotiline                                    12                    Amelin (2000)           0.76 (0.32--1.8)                  

### Anticonvulsants {#sec013}

There were 32 trials comparing anticonvulsants to placebo with a total of 8529 participants who averaged 41 years (range 12--76) in age; 81% of participants were women ([Table 2](#pone.0130733.t002){ref-type="table"}). Twenty-seven of these trials focused on episodic migraine headaches ([Table 2](#pone.0130733.t002){ref-type="table"}), five evaluated chronic migraine and four chronic daily headaches ([Table 3](#pone.0130733.t003){ref-type="table"}). The average rate of withdrawals was 23%. Studies averaged 15 weeks (range 4--82) with a mean of 153 participants (range 23--487). All of the studies reported headache frequency as their outcome. The two most commonly tested anticonvulsants were topiramate (n = 12) and valproate (n = 6). Other anticonvulsants tested included acetazolamide (n = 1), carbamazepine (n = 1), carisbamate (n = 1), clonazepam (n = 1), gabapentin (n = 4), lamotrigine (n = 1), levetiracetam (n = 3), oxcarbazepine (n = 1), and vigabatrin (n = 1).

In single trials, several anticonvulsants were no better than placebo for episodic migraines including acetazolamide, carbamazepine, carisbamate, clonazepam, oxcarbazepine and vigabatrin ([Table 5](#pone.0130733.t005){ref-type="table"}). In single trials, lamotrigine was found effective at 4 weeks though ineffective at 12 weeks ([Table 5](#pone.0130733.t005){ref-type="table"}). In several trials, gabapentin was not superior to placebo ([Table 5](#pone.0130733.t005){ref-type="table"}). Several of these anticonvulsants were assessed for ability to reduce headaches by 50% ([Table 7](#pone.0130733.t007){ref-type="table"}). Carisbamate was less effective than placebo and anticonvulsants no more likely than placebo to reduce headaches by at least 50% included acetazolamide, gabapentin, lamotrigine, levetiracetam and oxcarbazepine.

Anticonvulsants that were found to be more effective than placebo for episodic migraine included levetiracetam ([Table 6](#pone.0130733.t006){ref-type="table"}), topiramate ([Fig 4](#pone.0130733.g004){ref-type="fig"}) and valproate ([Fig 5](#pone.0130733.g005){ref-type="fig"}). Both topiramate and valproate had numerous trials demonstrating benefit at multiple time points ([Table 5](#pone.0130733.t005){ref-type="table"}).

![Topiramate compared to placebo for episodic migraine headaches.](pone.0130733.g004){#pone.0130733.g004}

![Valproate compared to placebo for episodic migraine headaches.](pone.0130733.g005){#pone.0130733.g005}

### Topiramate {#sec014}

Topiramate has been evaluated in twelve placebo-controlled trials that reported outcomes at numerous time points and different doses (50, 100 and 200mg). Pooled results suggest that topiramate was more effective than placebo at all time points (4--24 weeks, [Table 5](#pone.0130733.t005){ref-type="table"}) and at all doses assessed. There was evidence that higher doses of topiramate was more effective than lower ones, with a stepwise increase as the dose increased from 50 to 100 to 200mg ([Fig 6](#pone.0130733.g006){ref-type="fig"}). For chronic migraine, 2 studies of topiramate suggested effectiveness for up to 16 weeks ([Table 6](#pone.0130733.t006){ref-type="table"}). In several studies (n = 8) topiramate was also demonstrated to be more effective than placebo at reducing migraine by more than 50% ([Table 7](#pone.0130733.t007){ref-type="table"}).

![Dose response relationship of headache to topiramate dose.](pone.0130733.g006){#pone.0130733.g006}

### Valproate {#sec015}

Valproate also had been compared to placebo in six trials with multiple time points and varying doses (500-1500mg). Valproate was found to be more effective than placebo for episodic migraine at all time points assessed including 4, 8 and 12 weeks ([Table 5](#pone.0130733.t005){ref-type="table"}, [Fig 5](#pone.0130733.g005){ref-type="fig"}). However, unlike topiramate there was no evidence of a difference in response to increased doses (dose-response p = 0.83). Valproate was also found in numerous trials (n = 5) to reduce headaches by more than 50% ([Table 7](#pone.0130733.t007){ref-type="table"}).

### Beta Blockers {#sec016}

There were 38 trials comparing beta-blockers to placebo with a total of 2019 participants, 37 focusing on episodic ([Table 2](#pone.0130733.t002){ref-type="table"}) and 1 on chronic migraine headaches ([Table 3](#pone.0130733.t003){ref-type="table"}). The average rate of withdrawals was 18%. Study duration averaged 11 weeks (range 4--64) with a mean of 64 participants (range 20--568). The majority (82%) reported headache frequency, four trials used headache index, and one duration. There were a variety of beta-blockers tested including acebutolol (n = 1), alprenolol (n = 1), atenolol (n = 3), bisoprolol (n = 1), metoprolol (n = 4), oxprenolol (n = 1), pindolol (n = 2), propranolol (n = 19) and timolol (n = 4).

Beta blockers no more effective than placebo included acebutolol, alprenolol, bisoprolol, oxprenolol and pindolol ([Table 5](#pone.0130733.t005){ref-type="table"}). Beta-blockers superior to placebo for episodic migraine headaches ([Table 5](#pone.0130733.t005){ref-type="table"}) included atenolol, metoprolol, propranolol ([Fig 7](#pone.0130733.g007){ref-type="fig"}) and timolol. Seven studies found that propranolol reduced headache by 50% ([Table 7](#pone.0130733.t007){ref-type="table"}). Neither atenolol (1 study) nor propranolol (2 studies) were effective for chronic migraine ([Table 6](#pone.0130733.t006){ref-type="table"}).

![Propranolol compared to placebo for episodic migraine headaches.](pone.0130733.g007){#pone.0130733.g007}

### Calcium Channel Blockers {#sec017}

Calcium blockers headache trials tested cyclendelate (n = 1), nicardipine (n = 1), nifedipine (n = 2), nimodipine (n = 5) and verapamil (n = 2). All studies focused on episodic migraines ([Table 2](#pone.0130733.t002){ref-type="table"}). Overall there were a total of 878 participants who averaged 35 years in age (range 15--65) with 78% women. The average rate of withdrawals was 18%. Study duration averaged 11 weeks (range 4--20) with a mean of 52 participants (range 12--192). No calcium channel blocker was more effective than placebo, including cyclendelate, nicardipine, nifedipine, nimodipine and verapamil ([Table 5](#pone.0130733.t005){ref-type="table"}). When the dihydropyridines (nicardipine, nifedipine, nimodipine) were pooled, they were no better than placebo at reducing headaches.

### Flunarizine {#sec018}

While classified as a calcium channel blocker, flunarizine has no influence on blood pressure and its side effect profile suggests that its site of action is on cellular receptors other than the calcium channel \[[@pone.0130733.ref231],[@pone.0130733.ref232]\]. Flunarizine is not available in the United States. There were 7 studies of episodic migraines, totaling 332 participants ([Table 2](#pone.0130733.t002){ref-type="table"}). Studies averaged 47 participants, 36.4 years in age, 77% women, 12.5 weeks in duration and 9% dropouts. Four studies reported headache frequency and three reported headache outcomes based on a headache index. Flunarizine was superior to placebo at 8 and 12 weeks ([Table 5](#pone.0130733.t005){ref-type="table"}, [Fig 8](#pone.0130733.g008){ref-type="fig"}), though not at 4 weeks. Only a single trial reported the likelihood of a 50% reduction in headache with flunarizine with insignificant results ([Table 7](#pone.0130733.t007){ref-type="table"}).

![Flunarizine compared to placebo for episodic migraine headaches.](pone.0130733.g008){#pone.0130733.g008}

### Selective Serotonin Reuptake Inhibitors (SSRI)/ Selective Norepinephrine Reuptake inhibitors (SNRI) {#sec019}

There were six SSRI and one SNRI placebo controlled trials, five focusing on migraines and 1 on chronic daily headaches. There were a total of 335 participants who averaged 36.9 years in age (range 18--65) with 81% women ([Table 2](#pone.0130733.t002){ref-type="table"}). The average rate of withdrawals was 25% (range 0--41%). Study duration averaged 12 weeks (range 8--20) with a mean of 56 participants (range 27--111). Specific drugs tested include three SSRIs (femoxitine, n = 1, fluoxetine, n = 4 and sertraline, n = 1), and one SNRI (venlaxafine, n = 1). Four of the SSRI trials reported a headache index. One SSRI trial and the SNRI trial reported frequency of headaches per month.

For migraine headaches, two SSRI's, femoxitine and sertraline, were no more effective than placebo while fluoxetine was effective at 12 weeks ([Fig 9](#pone.0130733.g009){ref-type="fig"}). A single trial of venlafaxine found benefit at 8 weeks ([Table 5](#pone.0130733.t005){ref-type="table"}). For chronic daily headache a single trial of fluoxetine found no benefit ([Table 6](#pone.0130733.t006){ref-type="table"}). Only a single trial (fluoxetine) investigated the likelihood of reducing headaches by at least 50% and found no benefit over placebo ([Table 7](#pone.0130733.t007){ref-type="table"}).

![SSRI/SNRIs compared to placebo for episodic migraine headaches.](pone.0130733.g009){#pone.0130733.g009}

### Serotonin Antagonists {#sec020}

Pizotifen is a serotonin antagonist, commonly used for migraine treatment in the 1970's and 80's. There were 9 placebo controlled trials with a total of 600 participants and all focused on episodic migraine headaches ([Table 2](#pone.0130733.t002){ref-type="table"}). The average rate of withdrawals was 20% (range 0--48). Study duration averaged 8 weeks (range 4--12) with a mean of 67 participants (range 26--176). Two studies reported a headache index, the other 7 headache frequency. Pizotifen was superior to placebo at all time points ([Fig 10](#pone.0130733.g010){ref-type="fig"}, [Table 5](#pone.0130733.t005){ref-type="table"}). No trials reported on the likelihood of achieving at least 50% improvement in headaches.

![Pizotifen compared to placebo for episodic migraine headaches.](pone.0130733.g010){#pone.0130733.g010}

Tricyclic Antidepressants (TCA) {#sec021}
-------------------------------

There were 8 trials comparing a TCA to placebo, one focusing on chronic daily headaches, the remainder on episodic migraine headaches. There were a total of 1570 participants. The average rate of withdrawals was 37% (range 20--52%). Study duration averaged 10 weeks (range 4--24) with a mean of 143 participants (range 10--554). Tricyclic's studied included amitriptyline (n = 5), clomipramine (n = 2) doxepin (n = 1) and opipramol (n = 1). Four trials reported headache frequency and 4 used a headache index as their outcome measure.

For episodic migraines, amitriptyline, clomipramine and doxepin were better than placebo ([Table 5](#pone.0130733.t005){ref-type="table"}, [Fig 11](#pone.0130733.g011){ref-type="fig"}), while opipramol ([Table 5](#pone.0130733.t005){ref-type="table"}) was ineffective. Amitriptyline was the best studied TCA ([Fig 12](#pone.0130733.g012){ref-type="fig"}), though two of the studies were only 4 weeks in duration. Amitriptyline was more likely than placebo to produce a 50% reduction in episodic migraine headaches ([Table 7](#pone.0130733.t007){ref-type="table"}). A single trial found amitriptyline ineffective for chronic daily headaches ([Table 6](#pone.0130733.t006){ref-type="table"}).

![TCAs compared to placebo for episodic migraine headaches.](pone.0130733.g011){#pone.0130733.g011}

![Amitriptyline compared to placebo for migraine headaches.](pone.0130733.g012){#pone.0130733.g012}

Comparative Effective Trials {#sec022}
----------------------------

There were a total of 60 trials with comparisons between different prophylactic drugs for headaches, 55 including subjects with episodic headaches, five with chronic migraine headaches. Not all prophylactic drugs were directly compared with each other ([Table 8](#pone.0130733.t008){ref-type="table"}). Quality ratings for these trials are given in [Table 9](#pone.0130733.t009){ref-type="table"}. Drugs that were frequently compared to other active drugs include amitriptyline, metoprolol, pizotifen, propranolol, topiramate and valproate. There were few differences in effectiveness between the different drugs. Amitriptyline was no more effective than SSRIs, venlafaxine, topiramate or propranolol. Among beta-blockers, metoprolol was superior to clonidine, flunarizine and nifedipine and propranolol was better than femoxitine. Propranolol was equivalent to metoprolol, atenolol, nadolol as well as to flunarizine and topiramate ([Table 10](#pone.0130733.t010){ref-type="table"}). Among the anticonvulsants, topiramate was equivalent to flunarizine, lamotrigine and to valproate and valproate was equivalent to flunarizine. For chronic migraines, popranolol was better than nortriptyline.

10.1371/journal.pone.0130733.t008

###### Characteristics of comparative effectiveness trials.

![](pone.0130733.t008){#pone.0130733.t008g}

  Author, year, Country                                         Migraine Type                    Baseline Headache Frequency   Comparison Drugs                                                              Headache Measure            Study design (washout, weeks)   Duration, weeks   Sample size   Drop-outs   Age    Female
  ------------------------------------------------------------- -------------------------------- ----------------------------- ----------------------------------------------------------------------------- --------------------------- ------------------------------- ----------------- ------------- ----------- ------ --------
  **Episodic (\<15 headaches/month)**                                                                                                                                                                                                                                                                                       
  Afshari \[[@pone.0130733.ref180]\], 2012, Iran                Episodic                         7.6                           Topiramate (50) v. Valproate (400)                                            Frequency                   Parallel                        12                76            26%         30.7   79%
  Albers \[[@pone.0130733.ref181]\], 1989, USA                  Episodic                         4.3                           Propranolol (180) v. Nifedipine (90)                                          Frequency                   Parallel                        24                40            50%         35.2   85%
  Amelin\[[@pone.0130733.ref182]\], 2000, Russia                Episodic                         4.3                           Amitriptyline (25) v. Fluoxetine (20)                                         Frequency                   Parallel                        12                46            23%         36     95%
  Andersson \[[@pone.0130733.ref183]\], 1973, Denmark           Episodic                         2.3                           Pizotifen (2) v. Methysergide (4)                                             Frequency                   Crossover (0)                   12                73            33%         ns     84%
  Andersson \[[@pone.0130733.ref242]\], 1981, Denmark           Episodic                         5.7                           Propranolol (160) vs. Femoxetine (400)                                        Frequency                   Crossover (0)                   8                 49            24%         38     69%
  Ashtari \[[@pone.0130733.ref185]\], 2008, Iran                Episodic                         5.95                          Propranolol (80) v. Topiramate (50)                                           Frequency                   Parallel                        8                 62            3%          30.8   82%
  Bank \[[@pone.0130733.ref186]\], 1994, Hungary                Episodic                         ns                            Amitriptyline (25) v. Fluvoxamine (50)                                        Frequency                   Parallel                        12                44            23%         34     80%
  Bellavance \[[@pone.0130733.ref163]\], 1990, Canada           Episodic                         6.7                           Pizotifen (1.5) v. Naproxen (1100)                                            Frequency                   Parallel                        12                176           14%         32.5   79%
  Bordini \[[@pone.0130733.ref190]\], 1997, Brazil              Episodic                         3.9                           Propranolol (60) v. Flunarizine (10)                                          Headache Index              Parallel                        24                52            13%         ns     91%
  Bostani \[[@pone.0130733.ref191]\], 2013, Iran                Episodic                         6.1                           Valproate (400) v. Cinnarizine (50)                                           Frequency                   Parallel                        12                132           21%         32.2   68%
  Bulut \[[@pone.0130733.ref192]\], 2004, Turkey                Episodic                         3.5                           Amitriptyline (75) v Venlafaxine (150)                                        Frequency                   Crossover (4)                   12                52            32%         31.9   85%
  Cady \[[@pone.0130733.ref193]\], 2011, USA                    Episodic                         5.9                           Topiramate (100) v. frovatriptan (5- with aura)                               Frequency                   Parallel                        8                 55            20%         37.5   78%
  Cerbo \[[@pone.0130733.ref194]\], 1986, Italy                 Episodic                         ns                            Flunarizine (15) v. Pizotofen (1.5)                                           Frequency                   Crossover (2)                   8                 27            33%         ns     ns
  Diener \[[@pone.0130733.ref106]\], 1996, Germany              Episodic                         4                             Propranolol(120) v Cyclendalate (1200) v. Placebo                             Duration (hours)            Parallel                        12                214           17%         39     78%
  Diener \[[@pone.0130733.ref195]\], 2002, EU                   Episodic                         3                             Propranolol (160) v. Flunarizine (5) v. Flunarizine (10)                      Frequency                   Parallel                        16                783           18%         37     81%
  Diener \[[@pone.0130733.ref073]\], 2004, EU                   Episodic                         3.9                           Propranolol (160) v. Topiramate (100) v. Placebo                              Frequency                   Parallel                        26                568           37%         40.8   80%
  Dodick \[[@pone.0130733.ref196]\], 2009, USA                  Episodic                         6.9                           Amitriptyline (100) v. Topiramate (100)                                       Frequency                   Parallel                        26                331           43%         38.8   85%
  Formisano \[[@pone.0130733.ref198]\], 1991, Italy             Episodic                         4                             Propranolol (120) v. Nimodipine (120)                                         Frequency                   Parallel                        12                22            14%         39.2   55%
  Forssman \[[@pone.0130733.ref199]\], 1972, Sweden             Episodic                         6.8                           Pizotifen (3) v. methysergide (3)                                             Frequency                   Crossover (0)                   10                22            23%         40.3   53%
  Gawel \[[@pone.0130733.ref200]\], 1992, Canada                Episodic                         4.7                           Propranolol (160) v. Flunarizine (10)                                         Frequency                   Parallel                        16                94            19%         35.7   90%
  Gerber \[[@pone.0130733.ref201]\], 1991, Germany              Episodic                         3.5                           Propranolol (120) v. Metoprolol (200) v. Nifedipine (20)                      Frequency                   Parallel                        12                58            28%         42.4   81%
  Gupta \[[@pone.0130733.ref202]\], 2007, India                 Episodic                         6.9                           Topiramate (50) v. Lamotrigine (50)                                           Frequency                   Crossover (1)                   4                 57            7%          29.4   78%
  Havanka-Kannianen \[[@pone.0130733.ref141]\], 1987, Finland   Episodic                         5.2                           Nimodipine (120mg) v. Pizotifen (1.5) v. Placebo                              Frequency                   Crossover (4)                   12                43            14%         37.6   79%
  Hübbe \[[@pone.0130733.ref035]\], 1973, Denmark               Episodic                         ns                            Pizotifen (1.5) v. Prochlorperazine (15) v. Placebo                           Frequency                   Crossover (0)                   8                 50            32%         35     71%
  Kalita \[[@pone.0130733.ref204]\], 2013, India                Episodic                         10.8                          Amitriptyline (50) v. Valproate (1000)                                        Frequency                   Parallel                        24                300           0%          32     80
  Kangasniemi \[[@pone.0130733.ref167]\], 1979, Finland         Episodic                         6.2                           Pizotifen (1.5) v. Divascan (5) v. Placebo                                    Frequency                   Crossover (4)                   7                 50            13%         37     71%
  Kangasniemi \[[@pone.0130733.ref205]\], 1983, Finland         Episodic                         7.2                           Propranolol (160) v. Femoxitine (400)                                         Frequency                   Crossover (1)                   16                29            17%         37     86%
  Kangasniemi \[[@pone.0130733.ref116]\], 1984, Finland         Episodic                         5.3                           Propranolol (240) v. Metoprolol (200)                                         Frequency                   Crossover (3)                   8                 36            8%          33.8   89%
  Kaniecki \[[@pone.0130733.ref206]\], 1997, USA                Episodic                         4.4                           Dvalproex (1500) v. Propranolol (240) v. Placebo                              Headache Index              Parallel                        12                37            14%         ns     81%
  Kass \[[@pone.0130733.ref178]\], 1980, Norway                 Episodic                         ns                            Propranolol (40) v. Clonidine (0.05)                                          Frequency                   Crossover (0)                   16                23            9%          39.7   70%
  Keskinbora \[[@pone.0130733.ref207]\], 2008, Turkey           Episodic                         6.1                           Amitriptyline (150) v Topiramate (200)                                        Frequency                   Parallel                        12                63            16%         37     67%
  Krymchantowski \[[@pone.0130733.ref209]\], 2012, Brazil       Episodic                         7                             Topiramate (100) v. Nortriptyline (30) v. combination                         Frequency                   Parallel                        10                38            13%         36     85%
  Langohr \[[@pone.0130733.ref175]\], 1985, Germany             Episodic                         ns                            Clomipramine (100) v. Metoprolol (100) v. Placebo                             Frequency                   Crossover (4)                   4                 36            43%         44     67%
  Louis \[[@pone.0130733.ref210]\], 1982, Belgium/Netherlands   Episodic                         2.2                           Flunarizine (10) v. Pizotifen (3)                                             Frequency                   Crossover (0)                   16                75            ns          37     57%
  Louis \[[@pone.0130733.ref179]\], 1985, Belgium               Episodic                         ns                            Metoprolol (100) v. Clonidine (0.1)                                           Frequency                   Crossover (2)                   8                 33            6%          33.5   81%
  Lucking \[[@pone.0130733.ref211]\], 1988, Germany             Episodic                         6                             Propranolol (120) v Flunarizine (10)                                          Frequency                   Parallel                        16                434           23%         42     82%
  Ludin \[[@pone.0130733.ref212]\], 1989. Switzerland           Episodic                         6.3                           Propranolol (120) v. Flunarizine (10)                                         Frequency                   Parallel                        16                87            17%         42     74%
  Luo \[[@pone.0130733.ref213]\], 2012, China                   Episodic                         4.5                           Topiramate () v. Flunarizine (5) v. combination                               Frequency                   Parallel                        48                150           16%         43     71%
  Mathew \[[@pone.0130733.ref118]\], 1981, USA                  Unclear                          ns                            Amitriptyline (75) v Propranolol (160) v. Placebo                             Frequency                   Parallel                        24                554           22%         38     95%
  Mitsikostas \[[@pone.0130733.ref214]\], 1997, Greece          Episodic                         4.6                           Valproate (1000) v. Flunarizine (10)                                          Frequency                   Parallel                        8                 44            ns          35.4   73%
  Mohammadianinejad \[[@pone.0130733.ref215]\], 2011, Iran      Episodic                         7.4                           Topiramate (100) v. Zonisamide (200)                                          Frequency                   Parallel                        12                80            6%          34.3   69%
  Olerud \[[@pone.0130733.ref216]\], 1986, Sweden               Episodic                         4.6                           Propranolol (80) v. Nadolol (80)                                              Frequency                   Parallel                        12                28            ns          ns     ns
  Olsson \[[@pone.0130733.ref217]\], 1984, Sweden               Episodic                         5.4                           Propranolol (80) v. Metoprolol (100)                                          Frequency                   Crossover (4)                   8                 56            5%          39     73%
  Osterman \[[@pone.0130733.ref169]\], 1977, Sweden             Episodic                                                       Pizotifen (0.5) v. Divascan v. Placebo                                        Frequency                   Crossover (2)                   8                 30            10%         37     70%
  Presthus \[[@pone.0130733.ref218]\], 1971, Norway             Episodic                                                       Pizotifen (1.5) v. Methysergide (3)                                           Frequency                   Crossover (1)                   21                21            10%         42.7   67%
  Rampello \[[@pone.0130733.ref219]\], 2004, Italy              Episodic                                                       Amitriptyline (50) v. Citalopram (20)                                         Frequency                   Parallel                        16                88            0%          39     63%
  Rascol \[[@pone.0130733.ref220]\], 1986, France               Episodic                         4.3                           Flunarizine (10) v. Pizotifen (2)                                             Frequency                   Parallel                        16                35            9%          38     71%
  Ryan \[[@pone.0130733.ref170]\], 1968, USA                    Episodic                         8.5                           Pizotifen (4) v. Methysergide (4) v. Placebo                                  Frequency                   Crossover (0)                   4                 62            ns          ns     ns
  Ryan \[[@pone.0130733.ref221]\], 1984, USA                    Episodic                         6.5                           Propranolol (160) v. Nadolol (80) v. Nadolol (160)                            Frequency                   Parallel                        12                48            6%          ns     73%
  Scholz (188), 1987, Germany                                   Episodic                                                       Propranolol (80) v. Metoprolol (100) v. Nifedipine (40) v. Flunarizine (10)   Frequency                   Parallel                        12                109           24%         40.4   83%
  Shaygannejad \[[@pone.0130733.ref223]\], 2006, Iran           Episodic                         5.4                           Topiramate (50) v. Valproate (500)                                            Crossover (8)               Parallel                        8                 64            0%          34.1   60%
  Shimell \[[@pone.0130733.ref224]\], 1990, S Africa            Episodic                         4.7                           Propranolol (240) v. Flunarizine (10)                                         Frequency                   Parallel                        16                57            2%          34     70%
  Sorensen \[[@pone.0130733.ref225]\], 1991, Denmark            Episodic                         4.3                           Metoprolol (200) v. Flunarizine (10)                                          Frequency                   Parallel                        20                149           15%         42     79%
  Stovner, 2013, Norway                                         Episodic                                                       Candesartan (16), Propranolol (160)                                           Frequency                   Crossover                       12                61            15%         37     82%
  Sudilovsky \[[@pone.0130733.ref226]\], 1987, USA              Episodic                         5.3                           Nadolol (80) v. Nadolol (160)                                                 Frequency                   Parallel                        8                 168           20%         ns     ns
  Stensrud (107), 1980, Norway                                  Episodic                         5.6                           Propranolol (160) v. Atenolol (100) v. Placebo                                Crossover(1)Crossover (1)   Parallel                        6                 7             20%         25     69%
  Tarasova \[[@pone.0130733.ref227]\], 2008, Russia                                                                            Amitriptyline () v. Fluvoxamine ()                                            Frequency                   Parallel                                                                           
  Togha \[[@pone.0130733.ref228]\], 2008, Iran                  Episodic                         7.2                           Valproate (600) v. Cinnarizine (75)                                           Frequency                   Parallel                        12                125           37%         34.1   80%
  Vilming \[[@pone.0130733.ref229]\], 1985, Sweden/Norway       Episodic                         6                             Metoprolol (100) v. Pizotifen (1.5)                                           Frequency                   Crossover (0)                   4                 35            ns          37.6   83%
  Zain \[[@pone.0130733.ref230]\], 2013, Pakistan               Episodic                         11.32                         Topiramate (200) v. Gabapentin (1200)                                         Frequency                   Parallel                        12                80            0%          32     80%
  Ziegler \[[@pone.0130733.ref136]\], 1987, USA                 Episodic                         Ns                            Amitriptyline (150) v. Propranolol (240) v. Placebo                           Frequency                   Crossover (4)                   4                 30            44%         38     73%
  **Chronic Migraine (≥15 headaches/month)**                                                                                                                                                                                                                                                                                
  Bartolini \[[@pone.0130733.ref187]\], 2005, Italy             Chronic Migraine                 26.6                          Topiramate (75) v. Valproate (750)                                            Frequency                   Parallel                        8                 49            14%         41.8   70%
  Behan \[[@pone.0130733.ref188]\], 1986, UK                    Chronic Migraine                 15                            Pizotifen (1.5) v. Naproxen (1100)                                            Frequency                   Parallel                        12                74            45%         ns     82%
  Domingues \[[@pone.0130733.ref197]\], 2009, Brazil            Chronic Migraine                 16.7                          Nortriptyline (40) v. Propranolol (80)                                        Frequency                   Parallel                        6                 76            42%         ns     ns
  Krymchantowski \[[@pone.0130733.ref208]\], 2002, Brazil       Chronic (transformed) migraine   25.7                          Amitriptyline (40) v. Amitriptyline (40)+Fluoxetine (40)                      Frequency                   Parallel                        9                 39            44%         36.4   67%
  Stensrud (107), 1980, Norway                                  Chronic                          22                            Propranolol (160) v. Atenolol (100) v. Placebo                                Crossover(1)Crossover (1)   Parallel                        6                 28            20%         25     69%

10.1371/journal.pone.0130733.t009

###### Quality Assessment among comparative effectiveness trials.
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                                                                                            Cochrane Risk of Bias                                                                           
  ----------------------------------------------------------------------------------------- ----------------------- --------- ---------- ---------- --------- --------- --------- --------- ---------
  **EPISODIC MIGRAINES**                                                                                                                                                                    
  Afshari \[[@pone.0130733.ref180]\], 2012, Topiramate/valoproate                           4                       No        Unclear    Unclear    Unclear   No        Unclear   Unclear   No
  Albers \[[@pone.0130733.ref181]\], 1989, Propranolol/Nifedipine                           5                       No        Yes        Yes        No        No        No        No        Yes
  Amelin\[[@pone.0130733.ref182]\], 2000, Amitriptyline/Fluoxetine                          4                       No        No         Unclear    No        No        Unclear   Yes       No
  Andersson \[[@pone.0130733.ref183]\], 1973, Pizotifen/Methysergide                        4                       No        Unclear    Unclear    Unclear   Unclear   Unclear   Unclear   Yes
  Andersson \[[@pone.0130733.ref242]\], 1981, Propranolol/Femoxitine                        4                       No        Unclear    Unclear    Unclear   Unclear   Unclear   Unclear   Unclear
  Ashtari \[[@pone.0130733.ref185]\], 2008, Propranolol/Topiramate                          5                       No        Yes        Yes        Unclear   No        Yes       Unclear   Unclear
  Bank \[[@pone.0130733.ref186]\], 1994, Amitriptyiline/Fluvoxamine                         4                       No        Unclear    Unclear    Unclear   No        Unclear   Yes       Unclear
  Bartolini \[[@pone.0130733.ref187]\], 2005, Topiramate/Valproate                          3                       No        Unclear    Unclear    Unclear   Unclear   Unclear   Unclear   Unclear
  Behan \[[@pone.0130733.ref188]\], 1986, Pizotifen/Naproxen                                2                       No        Unclear    Unclear    Unclear   Unclear   Unclear   Unclear   Unclear
  Bellavance \[[@pone.0130733.ref163]\], 1990, Pizotifen/Naproxen                           3                       No        Unclear    Unclear    Unclear   Unclear   Unclear   Unclear   Unclear
  Bordini \[[@pone.0130733.ref190]\], 1997, Propranolol/Flunarizine                         4                       No        Unclear    Unclear    Yes       No        No        No        Unclear
  Bulut \[[@pone.0130733.ref192]\], 2004, Amitriptyline/Venlafaxine                         6                       No        Unclear    Unclear    Yes       No        Unclear   Yes       Yes
  Cady \[[@pone.0130733.ref193]\], 2011, Topiramate/Froyatriptan                            3                                 Unclear    Unclear    No        Unclear   Unclear   Unclear   Yes
  Cerbo \[[@pone.0130733.ref194]\], 1986, Flunarizine/Pizotifen                             6                       Yes       Unclear    Unclear    Yes       Unclear   Unclear   Unclear   Unclear
  Diener \[[@pone.0130733.ref106]\], 1996, Propranolol/Cyclendalate/Placebo                 4                       Yes       Unclear    Unclear    Unclear   Unclear   Unclear   Unclear   Unclear
  Diener \[[@pone.0130733.ref195]\], 2002, Propranolol/Flunarizine                          8                       No        Yes        Yes        Yes       No        Unclear   Unclear   Yes
  Diener \[[@pone.0130733.ref073]\], 2004, Propranolol/Topiramate/Placebo                   8                       Yes       Unclear    Unclear    Unclear   Yes       Yes       Unclear   Yes
  Dodick \[[@pone.0130733.ref196]\], 2009, Amitriptyline/Topiramate                         8                       No        Yes        Yes        Yes       Yes       Yes       Yes       Yes
  Domingues \[[@pone.0130733.ref197]\], 2009, Nortriptyline/Propranolol                     4                       No        Unclear    Unclear    Unclear   Unclear   Unclear   Unclear   Unclear
  Formisano \[[@pone.0130733.ref198]\], 1991, Propranolol/Nimodipine                        4                       No        Unclear    Unclear    No        No        No        No        Unclear
  Forssman \[[@pone.0130733.ref199]\], 1972, Pizotifen/Methyergide                          5                       No        Unclear    Unclear    t         Unclear   Unclear   Unclear   Unclear
  Gawel \[[@pone.0130733.ref200]\], 1992, Propranolol/Flunarizine                           4                       No        Unclear    Unclear    Unclear   No        No        Unclear   Yes
  Gerber \[[@pone.0130733.ref201]\], 1991, Propranolol/Metoprolol/Nifedipine                3                       No        Unclear    Unclear    Unclear   No        Yes       Unclear   Unclear
  Gupta, 2007, Lamotrigin/Topiramate/Placebo                                                8                       Yes       Yes        Yes        Yes       Unclear   Unclear   Unclear   Yes
  Havanka-Kannianen \[[@pone.0130733.ref141]\], 1987, Nimodipine/Pizotifen/Placebo          3                       No        Unclear    Unclear    Unclear   Unclear   Unclear   Unclear   Unclear
  Hübbe \[[@pone.0130733.ref035]\], 1973, Pizotifen/Prochlorperazine/Placebo                3                       No        Unclear    Unclear    Unclear   Unclear   Unclear   Unclear   Yes
  Kangasniemi \[[@pone.0130733.ref167]\], 1979, Pizotifen/Divascan/Placebo                  6                       No        50 (32%)   37 (71%)   Unclear   Unclear   Unclear   Unclear   Unclear
  Kangasniemi \[[@pone.0130733.ref205]\], 1983, Propranolol/Femoxitine                      2                       No        Unclear    Unclear    Unclear   Unclear   Unclear   Unclear   Unclear
  Kangasniemi \[[@pone.0130733.ref116]\], 1984, Propranolol/Femoxitine/Placebo              2                       No        29 (17%)   37 (86%)   Unclear   Unclear   Unclear   Unclear   Unclear
  Kaniecki \[[@pone.0130733.ref206]\], 1997, Divalproex/Propranolol/Placebo                 4                       No        Unclear    Unclear    Unclear   Unclear   Unclear   Unclear   Unclear
  Kaas, 1980, Norway, Propranolol/Clonidine                                                 4                       Unclear   Unclear    Unclear    Unclear   Unclear   Unclear   Unclear   No
  Keskinbora \[[@pone.0130733.ref207]\], 2008, Amitiprytilne/Topiramate                     6                       No        Unclear    Yes        Yes       No        Yes       Yes       Unclear
  Krymchantowski \[[@pone.0130733.ref208]\], 2002, Amitriptyline/Amitriptyline+Fluoxetine   5                       No        Unclear    Unclear    Yes       Unclear   Unclear   Unclear   No
  Krymchantowski \[[@pone.0130733.ref209]\], 2012, Topiramate/Nortiptyline/Combination      8                       No        Yes        Yes        Yes       Unclear   Unclear   Unclear   Unclear
  Langohr \[[@pone.0130733.ref175]\], 1985, Clomipramine/Metoprolol/Placebo                 4                       No        Unclear    Unclear    Unclear   No        No        Yes       Yes
  Louis \[[@pone.0130733.ref210]\], 1982, Flunarizine/Pizotifen                             4                       No        Unclear    Unclear    Unclear   Unclear   Unclear   Unclear   Unclear
  Louis, 1985, Metoprolol/Clonidine                                                         4                       Unclear   Unclear    Unclear    Unclear   Unclear   Unclear   Unclear   No
  Lucking \[[@pone.0130733.ref211]\], 1988, Propranolol/Flunarizine                         4                       No        Unclear    Unclear    Unclear   Unclear   Unclear   Unclear   Yes
  Ludin \[[@pone.0130733.ref212]\], 1989, Propranolol/Flunarizine                           3                       Yes       Unclear    Unclear    Unclear   Unclear   Unclear   Unclear   Unclear
  Luo \[[@pone.0130733.ref213]\], 2012, Topiramate/Flunarizine/Combination                  2                                 Unclear    Unclear    Unclear   Unclear   Unclear   Unclear   Unclear
  Mathew \[[@pone.0130733.ref118]\], 1981, Amitriptyline/Propranolol/Placebo                2                       No        Unclear    Unclear    No        No        No        Yes       Unclear
  Mitsikostas \[[@pone.0130733.ref214]\], 1997, Valproate/Flunarizine                       4                       No        Unclear    Unclear    No        Unclear   Unclear   Unclear   Unclear
  Mohammadianinejad \[[@pone.0130733.ref215]\], 2011, Topiramate/Zonisamide                 6                       No        Unclear    Unclear    Yes       Unclear   Unclear   Unclear   Unclear
  Olerud \[[@pone.0130733.ref216]\], 1986, Propranolol/Nadolol                              4                       No        Unclear    Unclear    Yes       Unclear   Unclear   Unclear   Unclear
  Olsson \[[@pone.0130733.ref217]\], 1984, Propranolol/Metoprolol                           6                       No        Unclear    Unclear    Yes       Unclear   Unclear   Unclear   Unclear
  Osterman \[[@pone.0130733.ref169]\], 1977, Pizotifen/Divascan/Placebo                     5                       No        Unclear    Unclear    Yes       Unclear   Unclear   Unclear   Unclear
  Presthus \[[@pone.0130733.ref218]\], 1971, Pizotifen/Methysergide                         1                       No                   Unclear    Unclear   Unclear   Unclear   Unclear   Unclear
  Rampello \[[@pone.0130733.ref219]\], 2004, Amitriptyline/Citalopram                       4                       Yes       Unclear    Unclear    No        Yes       Unclear   Yes       Unclear
  Rascol \[[@pone.0130733.ref220]\], 1986, Flunarizine/Pizotifen                            4                       No        Unclear    Unclear    Unclear   Unclear   Unclear   Unclear   Unclear
  Ryan \[[@pone.0130733.ref170]\], 1968, Pizotifen/Methysergide/Placebo                     5                       No        Unclear    Unclear    Unclear   Unclear   Unclear   Unclear   Unclear
  Ryan \[[@pone.0130733.ref221]\], 1984, Propranolol/Nadolol                                2                       Yes       Unclear    Unclear    Unclear   Unclear   Unclear   Unclear   Unclear
  Scholz (188), 1987, Propranolol/Metoprolol/Nifedipine/Flunarizine                         3                       No        Unclear    Unclear    Unclear   Unclear   Unclear   Unclear   Unclear
  Shaygannejad \[[@pone.0130733.ref223]\], 2006, Topiramate/Valproate                       4                       Yes       Unclear    Unclear    Unclear   Unclear   Yes       Unclear   Unclear
  Shimell \[[@pone.0130733.ref224]\], 1990, Propranolol/Flunarizine                         6                       Yes       Unclear    Unclear    Yes       No        No        Unclear   Yes
  Sorensen \[[@pone.0130733.ref225]\], 1991, Metoprolol/Flunarizine                         6                       No        Unclear    Unclear    Yes       Yes       Yes       Unclear   Unclear
  Stensrud (107), 1980, Propranolol/Atenolol                                                7                       No        Unclear    Unclear    Yes       Unclear   Unclear   Unclear   Yes
  Sudilovsky \[[@pone.0130733.ref226]\], 1987, Nadolol (two doses)                          5                       No        Unclear    Unclear    Yes       Unclear   Unclear   Unclear   Unclear
  Togha \[[@pone.0130733.ref228]\], 2008, Valproate/Cinnarizine                             8                       Yes       Yes        Yes        Yes       Yes       Yes       Yes       Unclear
  Vilming \[[@pone.0130733.ref229]\], 1985, Metoprolol/Pizotifen                            4                       No        Unclear    Unclear    Unclear   Unclear   Unclear   Unclear   Unclear
  Ziegler \[[@pone.0130733.ref136]\], 1987, Amitriptyline/Propranolol/Placebo               3                       No        Unclear    Unclear    Unclear   No        Unclear   Yes       No

10.1371/journal.pone.0130733.t010

###### Comparative Effectiveness Trial Outcomes.
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  Drug 1                                          Drug 2                       Study (year)               Standardized Mean Difference (95% CI)[δ](#t010fn001){ref-type="table-fn"}   Heterogeneity
  ----------------------------------------------- ---------------------------- -------------------------- --------------------------------------------------------------------------- ---------------------------------
  **Episodic Migraines (\<14 headaches/month)**                                                                                                                                       
  Amitriptyline                                   Fluoxetine                   Amelin (2000)              -0.14 (-0.85 to 0.58)                                                       
  Amitriptyline                                   Fluvoxamine                  Bank (1994)                0.37 (-0.20 to 0.93)                                                        
  **Amitriptyline**                               **SSRI**                     **Pooled SMD**             **0.17 (-0.32 to 0.65)**                                                    Q = 1.15, df = 1. I^2^ = 12.9%
  Amitriptyline                                   Maprotiline                  Amelin (2000)              -0.15 (-0.87 to 0.57)                                                       
  Amitriptyline                                   Topiramate                   Dodick (2009)              -0.08 (-0.30 to 0.13)                                                       
  Amitriptyline                                   Topiramate                   Keskinbora (2008)          0.31 (-0.30 to 0.92)                                                        
  **Amitriptyline**                               **Topiramate**               **Pooled SMD**             **0.01 (-0.32 to 0.33)**                                                    Q = 1.41, df = 1, I^2^ = 29.2%
  Amitriptyline                                   Venlafaxine                  Bulut (2004)               -0.12 (-0.51 to 0.26)                                                       
  Amitriptyline                                   Propranolol                  Ziegler (1987)             0.17 (-0.55 to 0.88)                                                        
  Flunarizine                                     Flunarizine + Topiramate     Luo (2012)                 0.21 (-0.23 to 0.64)                                                        
  Metoprolol                                      Flunarizine                  Scholz (1981)              -0.83 (-1.65 to -0.01)                                                      
  Metoprolol                                      Flunarizine                  Sorensen (1991)            -0.35 (-0.69 to -0.02)                                                      
  **Metoprolol**                                  **Flunarizine**              **Pooled SMD**             **-0.43 (-0.77 to -0.10)**                                                  Q = 1.06, df = 1. I^2^ = 5.8%
  Metoprolol                                      Nifedipine                   Gerber (1991)              -0.66 (-1.31 to -0.01)                                                      
  Metoprolol                                      Nifedipine                   Scholz (1987)              -0.92 (-1.78 to -0.06)                                                      
  **Metoprolol**                                  **Nifedipine**               **Pooled SMD**             **-0.75 (-1.27 to -0.24)**                                                  Q = 0.24, df = 1, I^2^ = 0.0%).
  Metoprolol                                      Clomipramine                 Langohr (1985)             -1.4 (-2.8 to 0.03)                                                         
  Metoprolol                                      Clonidine                    Louis (1985)               -0.54 (-1.07 to -0.01)                                                      
  Metoprolol                                      Pizotifen                    Vliming (1985)             -0.43 (-1.15 to 0.30)                                                       
  Pizotifen                                       Flunarizine                  Cerbo (1986)               0.19 (-0.74 to 1.12)                                                        
  Pizotifen                                       Flunarizine                  Louis (1982)               0.14 (-0.34 to 0.63)                                                        
  Pizotifen                                       Flunarizine                  Rascol (1986)              0.40 (-0.29 to 1.08)                                                        
  **Pizotifen**                                   **Flunarizine**              **Pooled SMD**             **0.22 (-0.14 to 0.59)**                                                    Q = 0.36, df = 2, I^2^ = 0.0%
  Pizotifen                                       Divascan                     Osterman (1977)            -0.38 (-1.14 to 0.39)                                                       ---
  Pizotifen                                       Methysergide                 Andersson (1973)           -0.17 (-0.74 to 0.40)                                                       
  Pizotifen                                       Methysergide                 Forsmann (1972)            0.10 (-0.66 to 0.85)                                                        
  Pizotifen                                       Methysergide                 Presthus (1971)            0.24 (-0.64 to 1.12)                                                        
  Pizotifen                                       Methysergide                 Ryan (1968)                -0.13 (-0.63 to 0.37)                                                       
  **Pizotifen**                                   **Methysergide**             **Pooled SMD**             **-0.06 (-0.37 to 0.26)**                                                   Q = 0.83, df = 3, I^2^ = 0.0%
  Pizotifen                                       Nimodipine                   Havanka (1987)             0.11 (-0.59 to 0.71)                                                        ---
  Pizotifen                                       Naproxen                     Bellavance (1990)          0.10 (-0.27 to 0.46)                                                        ---
  Pizotifen                                       Prochloperazine              Hübbe (1973)               -0.33 (-0.96 to 0.29)                                                       ---
  Propranolol                                     Atenolol                     Stensrud (1980)            0.02 (-0.84 to 0.88)                                                        ---
  Propranolol                                     Clonidine                    Kaas (1980)                0.03 (-0.58 to 0.63)                                                        ---
  Propranolol                                     Cyclandelate                 Diemer (1996)              -0.07 (-0.38 to 0.24)                                                       ---
  Propranolol                                     Femoxetine                   Andersson (1981)           -0.40 (-1.05 to 0.25)                                                       
  Propranolol                                     Femoxetine                   Kangasniemi (1983)         -2.03 (-2.66 to -1.39)                                                      
  **Propranolol**                                 **Femoxetine**               **Pooled SMD**             **-1.21 (-2.8 to -0.37)**                                                   Q = 17.35, df = 1, I^2^ = 88.5%
  Propranolol                                     Flunarizine                  Bordini (1997)             -0.32 (-0.40 to 1.05)                                                       
  Propranolol                                     Flunarizine                  Diener (2002)              -0.38 (-0.52 to -0.24)                                                      
  Propranolol                                     Flunarizine                  Gawel (1992)               0.58 (0.12 to 1.04)                                                         
  Propranolol                                     Flunarizine                  Lucking (1988)             -0.20 (-0.67 to 0.27)                                                       
  Propranolol                                     Flunarizine                  Ludin (1989)               -0.21 (-0.73 to 0.30)                                                       
  Propranolol                                     Flunarizine                  Scholz (1987)              -0.37 (-1.16 to 0.43)                                                       
  Propranolol                                     Flunarizine                  Shimell (1990)             -0.02 (-0.55 to 0.50)                                                       
  **Propranolol**                                 **Flunarizine**              **Pooled SMD**             **-0.04 (-0.34 to 0.26)**                                                   Q = 20.62, df = 6, I^2^ = 70.9%
  Propranolol                                     Metoprolol                   Olsson (1984)              0.00 (-0.46 to 0.46)                                                        
  Propranolol                                     Metoprolol                   Scholz (1987)              0.03 (-0.58 to 0.65)                                                        
  **Propranolol**                                 **Metoprolol**               **Pooled SMD**             **0.15 (-0.27 to 0.57)**                                                    Q = 1.14, df = 1, I^2^ = 12.6
  Propranolol                                     Nadolol                      Olerud (1986)              0.37 (-0.39 to 1.13)                                                        
  Propranolol                                     Nadolol                      Ryan (1984)                -0.42 (-1.15 to 0.27)                                                       
  Propranolol                                     Nadolol                      Sudilovsky (1987)          0.28 (-0.08 to 0.64)                                                        
  **Propranolol**                                 **Nadolol**                  **Pooled SMD**             **0.19 (-0.18 to 0.56)**                                                    Q = 2.81, df = 2, I^2^ = 28.9%
  Propranolol                                     Nifedipine                   Albers (1989)              0.84 (-0.12 to 1.79)                                                        
  Propranolol                                     Nifedipine                   Gerber (1991)              -0.63 (-1.30 to 0.05)                                                       
  Propranolol                                     Nifedipine                   Scholz (1987)              -0.46 (-1.29 to 0.37)                                                       
  **Propranolol**                                 **Nifedipine**               **Pooled SMD**             **-0.14 (-0.98 to 0.71)**                                                   Q = 10.41, df = 2, I^2^ = 61.6%
  Propranolol                                     Nimodipine                   Formisano (1991)           -0.19 (-1.10 to 0.73)                                                       ---
  Propranolol                                     Topiramate                   Ashtari (2008)             -0.24 (-0.27 to 0.75)                                                       
  Propranolol                                     Topiramate                   Diener (2004)              0.12 (-0.08 to 0.32)                                                        
  Propranolol                                     Topiramate                   **Pooled SMD**             **-0.02 (-0.30 to 0.33)**                                                   Q = 1.65, df = 2, I^2^ = 39.5%
  Topiramate                                      Flunarizine                  Luo (2012)                 0.23 (-0.07 to 0.53)                                                        
  Topiramate                                      Frovatriptan (abortive)      Cady (2011)                -0.49 (-1.09 to 0.11)                                                       
  Topiramate                                      Topiramate+Flunarizine       Luo (2012)                 0.35 (-0.07 to 0.78)                                                        
  Topiramate                                      Lamotrigine                  Gupta (2007)               -0.30 (-0.83 to 0.22)                                                       
  Topiramate                                      Topiramate + Nortriptyline   Krymchantowski (2012)      0.53 (0.04 to 1.02)                                                         
                                                                               Afshari (2012)             -0.32 (-0.85 to 0.20)                                                       
                                                                               Shaygannejad (2006)        -0.19 (-0.68 to 0.30)                                                       
  Topiramate                                      Valproate                    **Pooled SMD**             **-0.28 (-0.70 to 0.15)**                                                   Q = 0.09, df = 1, I^2^ = 0.0%
  Topiramate                                      Zonisamide                   Mohammadianinejad (2011)   -0.26 (-0.72 to 0.19)                                                       
  Valproate                                       Cinnarizine                  Togha (2008)               -0.07 (-0.42 to 0.28)                                                       
  Valproate                                       Flunarizine                  Mitsikostas (1997)         -0.06 (-0.67 to 0.56)                                                       
  **Chronic Migraine (\>15 headaches/month)**                                                                                                                                         
  Amitriptyline                                   Amitriptyline+Fluoxetine     Krymchantowski (2002)      -0.44 (-1.20 to 0.33)                                                       
  Pizotifen                                       Naproxen                     Behan (1986)               0.08 (-0.56 to 0.73)                                                        
  Propranolol                                     Atenolol                     Stensrud (1980)            0.08 (-1.40 to 1.56)                                                        
  Propranolol                                     Nortriptyline                Domingues (2009)           -0.83 (-0.06 to -1.61)                                                      
  Topiramate                                      Valproate                    Bartolini (2005)           -0.13 (-0.72 to 0.46)                                                       

δ negative number favors drug 1, positive number favors drug 2 in these comparisons.

Network Meta-analysis {#sec023}
---------------------

Candidate drugs for the network meta-analysis were those drugs found effective for treatment of episodic migraine headaches with at least 3 randomized clinical trials. These included eleven different drugs used in prophylaxis of episodic migraine headaches ([Fig 13](#pone.0130733.g013){ref-type="fig"}). Indirect comparisons of these eleven individual drugs using meta-regression suggested that amitriptyline was more effective than several of the other drugs including candesartan (p = 0.04), fluoxetine (p = 0.03), propranolol (p = 0.009), topiramate (p = 0.005) and valproate (p = 0.009, [Fig 12](#pone.0130733.g012){ref-type="fig"}), and no different than atenolol (p = 0.20), flunarizine (p = 0.06), clomipramine (p = 0.15) or metoprolol (p = 0.15). The network meta-analysis found no differences between the other drugs in the relative effectiveness in the prophylaxis against migraine headaches. (p = 0.21).

![Network meta-analysis](pone.0130733.g013){#pone.0130733.g013}

Placebo effect {#sec024}
--------------

There were 78 studies that provided baseline headache frequency that included 4579 episodic migraine sufferers who were randomized to placebo. On average, patients randomized to the placebo group experienced 5.3 (95% CI: 4.9--5.8) headaches/month at baseline. Patients receiving placebos experienced a significant decline in headache frequency by 4 weeks, an effect that persisted through 12 weeks. By weeks 16, 20 and 24, the number of headaches experienced by patients given placebo increased back to values that were not different than baseline ([Fig 14](#pone.0130733.g014){ref-type="fig"}).

![Placebo effect of treatment of episodic migraine headaches.](pone.0130733.g014){#pone.0130733.g014}

Side Effects {#sec025}
------------

Patients receiving prophylactic treatment were more likely than those receiving placebo to experience side effects (RR: 1.27, 95% CI: 1.19 to 1.37) and to withdraw from treatment (RR: 1.18, 95% CI: 1.08--1.29). The specific side effects varied by study medication ([Table 11](#pone.0130733.t011){ref-type="table"}). Drowsiness was the most common side effect, increased among patients taking gabapentin, pizotifen, topiramate, TCA and valproate. Tricyclic antidepressants also caused dry mouth and weight gain. Beta-blockers were associated with feeling depressed, dizzy and insomnia. Topiramate increased rates of nausea and paresthesia. Pizotifen had marked increased rates of weight gain with participants averaging 4.3 kg (95% CI: 3.0--5.6).

10.1371/journal.pone.0130733.t011

###### Side Effects Compared with Placebo.

![](pone.0130733.t011){#pone.0130733.t011g}

                          Alpha Blockers      Anti-convulsants    Beta Blockers       Calcium Channel Blockers   Flunarizine                     SSRI                TCA
  ----------------------- ------------------- ------------------- ------------------- -------------------------- ------------------------------- ------------------- ---------------------------
  **"Any" side effect**   1.25 (0.91--1.71)   1.20 (1.14--1.27)   1.65 (1.41--1.93)   1.25 (1.03--1.53)          1.26 (0.67--2.37)               1.0 (0.51--1.97)    1.54 (1.37--1.74)
  **Withdrawal**          1.07 (0.65--1.78)   1.23 (1.13--1.34)   1.29 (1.03--1.61)   1.14 (0.84--1.57)          1.0 (0.3--3.2)                  1.13 (0.79--1.61)   1.53 (1.27--1.85)
  **Depression**          3.0 (0.13--70.6)    ns                  4.1 (1.1--15.2)     0.2 (0.01--4.0)            0.7 (0.1--3.4)                  ns                  ns
  **Dizziness**           1.80 (0.36--9.08)   1.61 (1.16--2.21)   1.75 (1.04--2.95)   1.19 (0.45--3.18)          ns                              1.28 (0.23--7.14)   1.20 (0.77--1.86)
  **Fatigue**             2.65 (0.94--7.51)   2.22 (1.67--2.96)   1.19 (0.90--1.56)   3.07 (1.26--7.48)          1.3 (0.7--2.1)                  ns                  1.84 (1.25--2.71)
  **Dry Mouth**           7.09 (2.31--21.7)   2.33 (0.43--12.8)   ns                  0.21 (0.01--4.27)          0.26 (0.03--2.3)                ns                  2.32 (1.63--3.28)
  **Nausea/vomiting**     1.50 (0.27--8.3)    1.44 (1.01--2.03)   1.8 (1.05--3.02)    0.68 (0.37--1.24)          0.12 (0.01--2.0) (1 study)      2.15 (0.80--5.8)    1.18 (0.42--3.3)
  **Parasthesias**        6.2 (1.5--26.3)     4.2 (2.7--6.6)      1.4 (0.49--4.2)     5.0 (0.25--101.9)          ns                              ns                  1.5 (0.26--9.0) (1 study)
  **Sleep disturbance**   Ns                  0.84 (0.53--1.33)   1.64 (1.08--2.5)    Ns                         ns                              1.27 (0.66--2.5)    0.63 (0.36--1.1)
  **Weight gain**         Ns                  1.02 (0.12--8.5)    6.1 (0.73--51.3)    3.08 (0.60--15.9)          0.79 (0.36--1.71) (4 studies)   ns                  1.65 (1.02--3.04)

Network meta-analysis and direct comparisons found no difference in likelihood of experiencing "any" side effect or in the rate of withdrawing from studies.

Sensitivity Analysis {#sec026}
--------------------

There was evidence of publication bias for beta-blockers (Egger p = 0.02), and for each of topiramate (p = 0.001) and valproate (p = 0.04). There was no evidence of publication bias for the remaining drugs or classes. The metatrim test reduced the effect estimate four these four drugs, though only for valproate did the adjusted effect become insignificant (beta-blocker SMD: -0.24, 95% CI: -0.45 to -0.04; topiramate: SMD: -0.35, 95% CI: -0.57 to -0.12; valproate: SMD: -0.40, 95% CI: -0.90 to 0.10).

There were a number of quality problems (Tables [4](#pone.0130733.t004){ref-type="table"} and [9](#pone.0130733.t009){ref-type="table"}). However, total Jadad score (p = 0.51), intention to treat (p = 0.84), sequence generation (p = 0.47), concealed allocation (p = 0.18), blinding (p = 0.84) or industry sponsorship (p = 0.17) had no relationship or impact on pooled outcomes.

The amount of heterogeneity varied considerably among the various drugs and drug classes. Longer duration of treatment was associated with greater effects for tricyclic antidepressants (β = -0.06, 95% CI: -0.09 to -0.03) as well as for valproate (β = -0.02, 95% CI -0.04 to -0.01) and flunarizine (β = -0.03, 95% CI -0.07 to -0.001). The other treatment options did not appear to be time-sensitive. There was no relationship between type of measurement (frequency vs. headache index) and outcomes (p = 0.72). Age, percent women, sample size, dropout rate, percent of maximum dose attained, study design and whether or not depressed patients were allowed to participate had no relationship with outcomes.

Discussion {#sec027}
==========

There has long been consensus that some drugs are useful in prophylaxis against migraine headaches. Our review confirms that there is good evidence for amitriptyline, atenolol, flunarizine, fluoxetine, metoprolol, pizotifen, propranolol, timolol, topiramate and valproate in reducing episodic migraine headache. At baseline, episodic migtaine sufferers averaged slightly over six headaches per month and most drugs reduced the number of headaches by 1 or 2 per month. Amitriptyline had the greatest benefit and while the network meta-analysis suggested that it was the most effective drug for preventing migraine headaches, this was not confirmed in clinical trials in which amitriptyline was directly compared with other drugs (including SSRIs, topiramate and propranolol), though all candidate drugs have not been included. Beta-blockers (atenolol, propranolol, timolol), anticonvulsants (topiramate, valproate), flunarizine and pizotifen had moderate benefit in reducing headache burden while the serotonin reuptake inhibitors had a small effect.

On average, across the effective prophylactic medications, migraine sufferers had about twice the chance of experiencing at least a 50% reduction in headaches as those receiving placebo. Our pooled risk reduction (ARR: 0.15, 95% CI: 0.09--0.21) suggests that 7 people would need to be treated to produce 50% reduction in headache burden in one subject. Side effects were common, but were predictable based on the drug mechanisms of action and are well-known.

There was a significant placebo effect that was seen within 4 weeks of placebo initiation with a gradual increase in the benefit of placebo on headaches through 12 weeks. By week 16, patients randomized to placebo had a gradual increase in the number of headaches experienced with no difference from baseline through 24 weeks of treatment. This is similar to the placebo effect we saw in our meta-analysis of pediatric migraine trials \[[@pone.0130733.ref233]\]. Uncontrolled trials of drugs for treatment of migraine headaches are still published, our data reinforces the importance of placebo controls.

Our study is the first to pool all the data from the numerous randomized controlled clinical trials to explore potential differences for both continuous and dichotomous outcomes and for both episodic and chronic migraine headaches. We also avoid a common error found in previous meta-analyses in which researchers pooled the outcome at the end of the study, regardless of the time point. This inappropriately pooled studies of different treatment durations.

There have been no previous systematic reviews of ACE/ARB, flunarizine or beta-blockers other than propranolol for migraine headaches. A recent Neurology Academy review was limited by several factors: 1) it included only studies since 2009, 2) it provided only qualitative statements about the level of evidence with no formal pooling of data and 3) it had no comparative effectiveness data \[[@pone.0130733.ref027]\]. While our findings are similar to previous reviews of anticonvulsants \[[@pone.0130733.ref234]\], the beta-blocker propranolol \[[@pone.0130733.ref235]\], anticonvulsants \[[@pone.0130733.ref236]\] and tricyclic antidepressants \[[@pone.0130733.ref237]\], we found some important differences. Anticonvulsants were less effective than a 2004 Cochrane review\[[@pone.0130733.ref234]\], though our review includes nearly twice as many studies. A 2004 Cochrane beta-blocker review included exclusively propranolol, while we include all beta-blockers. Our 2010 TCA review\[[@pone.0130733.ref237]\] inappropriately pooled both migraine and tension headaches together. Our 1996 review \[[@pone.0130733.ref238]\] also combined migraine and tension headaches, likely inappropriate given potentially important pathophysiologic differences. A 2005 Cochrane review of SSRIs found no benefit\[[@pone.0130733.ref239]\], but that trial was largely based on tension headaches and it also combined both migraine and tension headaches in their pooled analysis. In contrast, our larger review focuses on migraine headaches and suggests a modest effect from fluoxetine. To date, there have been no quantitative systematic reviews comparing the different classes of treatment, though one recent qualitative systematic review concluded that the choice should be tailored to patients based on side effects and comorbidities \[[@pone.0130733.ref240]\].

A recent systematic review examined the efficacy of prophylactic treatment for episodic migraine headaches\[[@pone.0130733.ref028]\] in reducing headaches by 50%, a dichotomous outcome. Our study includes both continuous and dichotomous outcomes and examines the effects for both episodic and migraine headaches. That study was limited to English language only and includes a smaller number of studies than this analysis. Our results are similar and in agreement with their conclusion that there is no difference in efficacy between the different drugs; however we found that the benefit for most drugs was less than they reported.

Our study has a number of important limitations. First the pooled differences between the various drugs and classes suggested important clinical differences. Some drugs had a large effect in headache reduction, others only small or modest ones. Our network meta-analysis suggested superiority for amitriptyline, a finding not confirmed in head-head trials. While there have been 51 trials directly comparing different drugs, these comparisons have been somewhat haphazard and many important potential comparisons have not been made.

Conclusions {#sec028}
===========

Our data suggests that the current practice of tailoring prophylactic medication according to patient characteristics and expected side effects is a good approach. Patients with migraine headaches and hypertension should consider trials with a beta blocker. Patients with depression may benefit from either SSRI or TCA. Patients with restless leg syndrome or another indication for an anticonvulsant may benefit from topiramate or valproate. Our analysis suggests that amitryptyline is more effective than the other medications, this has not been confirmed in the limited number of direct comparative effectiveness trials that have been conducted. The placebo effect, that lasts through at least 12 weeks in our study, suggests that non-placebo controlled trials should not be performed. Nearly all studies of headache treatment were 24 weeks or less in duration, this is an important limitation since migraine is a chronic condition. Whether treatment benefit persists, increases or wanes is unknown and deserving of further studies. The paucity of head-to-head comparative effectiveness trials between some classes of medication also indicates a direction for future headache research.
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